

Genome-wide association study of long COVID

Received: 15 June 2024

Accepted: 27 January 2025

Published online: 21 May 2025

 Check for updates

A list of authors and their affiliations appears at the end of the paper

Infections can lead to persistent symptoms and diseases such as shingles after varicella zoster or rheumatic fever after streptococcal infections. Similarly, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection can result in long coronavirus disease (COVID), typically manifesting as fatigue, pulmonary symptoms and cognitive dysfunction. The biological mechanisms behind long COVID remain unclear. We performed a genome-wide association study for long COVID including up to 6,450 long COVID cases and 1,093,995 population controls from 24 studies across 16 countries. We discovered an association of *FOXP4* with long COVID, independent of its previously identified association with severe COVID-19. The signal was replicated in 9,500 long COVID cases and 798,835 population controls. Given the transcription factor *FOXP4*'s role in lung physiology and pathology, our findings highlight the importance of lung function in the pathophysiology of long COVID.

The coronavirus disease 2019 (COVID-19) pandemic has led to the recognition of a new condition known as postacute sequelae of COVID-19 (PASC), post-COVID-19 condition or long COVID. The World Health Organization's definition includes any symptoms that present typically within three months after COVID-19 and persist for at least two months¹. Common symptoms include fatigue, pulmonary dysfunction, muscle and chest pain, dysautonomia and cognitive disturbances^{2–6}. The incidence of long COVID varies widely, with estimates in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-infected individuals ranging from 10% to 70%⁷. Long COVID is more common in individuals who have been hospitalized or treated at the intensive care unit due to COVID-19 (refs. 7,8). However, long COVID can also occur in those with initially mild COVID-19 symptoms⁹. Moreover, several mechanisms may contribute to long COVID, including alterations of the serotonin system that may be related to cognitive changes¹⁰, mitochondrial mechanisms to fatigue¹¹ and mechanisms involving complement and platelet activation to vascular disease observed in patients with long COVID¹².

The COVID-19 Host Genetics Initiative (COVID-19 HGI) was launched to investigate host genetics in COVID-19 susceptibility, hospitalization and critical illness^{13–16}. These findings implicate canonical pathways involved in viral entry, mucosal airway defense and type I interferon response^{15–18}.

To elucidate biological mechanisms behind long COVID, we conducted a genome-wide association study (GWAS) and replication in

33 cohorts across 19 countries, totaling 15,950 individuals with long COVID and 1,892,830 controls (Fig. 1).

Results

Genetic variants in *FOXP4* locus associated with long COVID

We performed a meta-analysis of 24 independent GWAS of long COVID using two case definitions and two control definitions. A strict long COVID case definition required having an earlier test-verified SARS-CoV-2 infection (strict case definition), while a broader long COVID case definition also included self-reported or clinician-diagnosed SARS-CoV-2 infection (broad case definition). The broad definition included all contributing studies, whereas the strict definition included 11 studies (Supplementary Tables 11 and 12). Controls were either population controls, or participants that had recovered from SARS-CoV-2 infection without long COVID (strict control definition; Fig. 1 and Supplementary Tables 11 and 12). Data were obtained from 16 countries, representing populations from six genetic ancestries. The most common symptoms in the questionnaire-based studies were fatigue, shortness of breath and problems with memory and concentration. However, there was some heterogeneity in the frequency of symptoms (Supplementary Fig. 1).

The GWAS meta-analysis using the strict case definition ($n = 3,018$) and the broad control definition ($n = 994,582$) identified a genome-wide significant association within the *FOXP4* locus (chr6: 41,515,652 G > C,

✉ e-mail: hugo.zeberg@ki.se; hanna.m.ollila@helsinki.fi




Fig. 1 | Geographic overview of studies contributing to the Long COVID HGI. The 24 studies contributing to the Long COVID HGI data freeze 4 served as the discovery cohorts for the GWAS meta-analyses. Each color represents a meta-analysis with specific case and control definitions. Strict case definition, long COVID after test-verified SARS-CoV-2 infection; broad case definition, long COVID after any SARS-CoV-2 infection; strict control definition, individuals

that had SARS-CoV-2 but did not develop long COVID; broad control definition, population control, that is, all individuals in each study that did not meet the long COVID criteria. Effective sample sizes are shown as the size of each diamond shape, and locations of sample collection in (from left to right) North America, Europe, Middle East and Asia. For more detailed sample sizes, see Supplementary Table 11.

Genome Reference Consortium Human Build 38 (GRCh38), **rs9367106**, as the lead variant; $P = 1.8 \times 10^{-10}$; Fig. 2 and Supplementary Table 13). The C allele at **rs9367106** was associated with an increased risk of long COVID (odds ratio (OR) = 1.63, 95% confidence interval (CI) = 1.40–1.89, risk allele frequency = 4.2%). The association replicated in an independent sample from eight additional contributing cohorts with 5,226 individuals with long COVID and 260,036 population controls ($P = 0.025$, OR = 1.13, 95% CI = 1.02–1.25; Supplementary Fig. 3d). Furthermore, the lead variants **rs9367106** and **rs12660421** replicated in the VA Million Veteran Program (MVP) in the strict case analyses with the broad control definition ($P = 1 \times 10^{-4}$, OR = 1.21, 95% CI = 1.10–1.34, long COVID cases, $n = 4,274$ and controls, $n = 538,799$; Supplementary Fig. 3e,f) and with the strict control definition ($P = 0.0018$, OR = 1.17, 95% CI = 1.06–1.29, long COVID cases, $n = 4,274$ and controls, $n = 73,739$; Supplementary Fig. 3g,h).

We observed an association, albeit not genome-wide significant, with **rs9367106**-C and long COVID also in all other three meta-analyses, including our largest meta-analysis with the broad case definition ($n = 6,450$) and the broad control definition ($n = 1,093,995$) from 24 studies (OR = 1.34, 95% CI = 1.20–1.49, $P = 1.1 \times 10^{-7}$; Supplementary Figs. 2 and 3). Analyses with the strict case definition ($n = 2,964$) and strict control definition ($n = 37,935$; OR = 1.30, 95% CI = 1.09–1.56, $P = 3.8 \times 10^{-3}$), and with the broad case definition ($n = 6,396$) and strict control definition ($n = 46,208$; OR = 1.16, 95% CI = 1.02–1.32, $P = 0.023$), further supported our findings (Supplementary Fig. 3).

To examine the consistency of the *FOXP4* signal across the contributing studies, we investigated the effect in each study (Fig. 2b). Genetic variants in the meta-analysis had varying statistical power

due to missingness, due to genotyping and imputation quality, and due to differences in allele frequency differences between populations. Therefore, the genetic variant that was present in majority of the studies was the most statistically significant variant, not necessarily because it is the causal variant but because it had the best statistical power. We, therefore, examined the effect size of variants within 30 kb around the lead variant (**rs9367106**, $r^2 > 0.01$ in individuals of Europeans in the Human Genome Diversity Project¹⁹ and 1000 Genomes Project^{20,21}) and effective sample size of at least one-third the sample size of the lead variant. Through this analysis, we identified a haplotype spanning the genomic region chr6:41,512,355–41,537,458 located upstream of *FOXP4* gene (Fig. 3d), for which variants had P values less than 5×10^{-7} (Fig. 3a) and effect sizes similar to the lead variant across ancestries (Fig. 3b,c). This analysis identified 15 variants (Supplementary Table 14). Relying on linkage disequilibrium (LD) in the 1000 Genomes Project across African, East Asian European, admixed American and South Asian populations, we found 18 variants cosegregating with the lead variant with tightest LD at the end of the haplotype ($r^2 > 0.5$; Supplementary Table 15). Nine variants overlapped between these two analyses.

Frequency of long COVID variants varies across ancestries

The allele frequency of **rs9367106**-C at the *FOXP4* locus varied across the study populations ranging from 1.6% in non-Finnish Europeans to 7.1% in Finnish, 19% in admixed Americans and 36% in East Asians (Supplementary Fig. 4; https://gnomad.broadinstitute.org/variant/6-41515652-G-C?dataset=gnomad_r3). Most of the contributing studies comprised individuals of European ancestry (Supplementary Fig. 5).




Fig. 2 | Meta-analysis of 11 GWAS studies of long COVID shows an association at the *FOXP4* locus. a, Manhattan plot of long COVID after test-verified SARS-CoV-2 infection (strict case definition, $n = 3,018$) compared to all other individuals in each dataset (population controls, broad control definition, $n = 994,582$). A genome-wide significant association with long COVID was found in the chromosome 6, upstream of the *FOXP4* gene (chr6:41,515,652 G:C, GRCh38, rs9367106, as the lead variant; $P = 1.76 \times 10^{-10}$, Bonferroni $P = 7.06 \times 10^{-10}$, increased risk with the C allele, OR = 1.63, 95% CI = 1.40–1.89). Horizontal lines indicate genome-wide significance thresholds for IVW meta-analysis before ($P < 5 \times 10^{-8}$, dashed line) and after (1.25×10^{-8}) Bonferroni correction over the four long COVID meta-analyses (INCMNSZ = MexGen-COVID Initiative).

b, Chromosome 6 lead variant across the contributing studies and ancestries in GWAS meta-analyses of long COVID with strict case definition and broad control definition. Lead variant rs9367106 (solid line) and if missing, imputed by the variant with the highest LD with the lead variant for illustrative purpose, that is, rs12660421 ($r = 0.98$ in European in 1,000 G + HGP samples⁵⁵, dotted lines). For the imputed variants, β was weighted by multiplying by the LD correlation coefficient ($r = 0.98$). Centre, OR; error bar, 95% CI. Genetic ancestries marked by colors. MAF varies across ancestries, ranging from 1% to 34% (Supplementary Fig. 4). AFR, African; AMR, Admixed American; EAS, East Asian; EUR, European; UKBB, UK Biobank. (Results for the other three GWAS meta-analyses in Supplementary Figs. 2 and 3a–c).

Despite smaller sample sizes, we observed significant associations in admixed American, East Asian and Finnish ancestries (Fig. 2b), owing to the higher allele frequency, and thus larger statistical power to detect an association with the rs9367106 variant in these cohorts.

Risk variants, *FOXP4* expression and COVID-19 severity
We next investigated whether the long COVID variants were associated with differential expression of any of the surrounding genes within a 100-kb window (*FOXP4*, *FOXP4-AS1*, *LINC01276* and *MIR4641*). We found




Fig. 3 | The chromosome 6 region (chr6: 41,490,001–41,560,000 (70 kb); *FOXP4* locus) in the long COVID GWAS meta-analysis. Long COVID meta-analysis with strict case ($n = 3,018$) and broad control ($n = 994,582$) definition (Fig. 2). X axis shows the position on chromosome 6 (GRCh38). The long COVID lead variant (rs9367106) is depicted with a triangle in each plot. **a**, Locus zoom plot with each variant colored by effective sample size and showing statistical

significance (IVW GWAS meta-analysis $-\log_{10}P$ value) on y axis. **b**, Each variant colored by statistical significance and showing effect sizes (center, coefficients; error bar, 95% CI on y axis). **c**, Each variant colored by ancestry and showing LD correlation coefficient (r) with the long COVID lead variant on y axis. **d**, Ensembl genes in the region (*FOXP4* not fully shown; www.ensembl.org)⁵⁶.

that rs12660421-A is associated with an increase in *FOXP4* expression in the lung ($P = 5.3 \times 10^{-9}$, normalized effect size (NES) = 0.56) and in the hypothalamus ($P = 2.6 \times 10^{-6}$, NES = 1.4; Fig. 4a and Supplementary Fig. 6; GTEx, <https://gtexportal.org/home/snp/rs12660421>). Furthermore, there were no additional expression quantitative trait loci (eQTL) or colocalization with the expression of *FOXP4-AS1* (Supplementary Table 16). *FOXP4* (HUGO Gene Nomenclature Committee ID: 20842) is a transcription factor gene that has a broad tissue expression pattern

and is expressed in nearly all tissues, with the highest expression in the cervix, the thyroid, the vasculature, the stomach and the testis²². The expression also spans a broad set of cell types, including endothelial lung cells, immune cells and myocytes²³. A colocalization analysis suggested that the association signal of long COVID is the same signal that associates with the differential expression of *FOXP4* in the lung (posterior probability = 0.91; Supplementary Fig. 7a,b and Supplementary Table 17).




Fig. 4 | *FOXP4* expression in the lung. a, The lead variant **rs9367106** was not found in the GTEx dataset, but a proxy variant (**rs12660421**, chr6: 41,520,640) in high LD ($r^2 = 0.97$, **rs12660421**-A allele is correlated with the long COVID risk allele **rs9367106**-C) showed a significant eQTL after multiple testing correction, increasing *FOXP4* expression in the lung ($P = 5.3 \times 10^{-9}$, NES; expression with GA genotype compared to expression with GG, normalized to 0) = 0.56; GTEx V8 lung samples with GG genotype, $n = 483$, GA genotype, $n = 32$; <https://gtexportal.org/home/snp/rs12660421>). For other tissues, see multitissue eQTL plot in Supplementary Fig. 6. **b**, Colocalization analysis using eQTL data from GTEx v8 tissue type and long COVID GWAS meta-analysis association data (Supplementary Note). Plots illustrate $-\log_{10} P$ value for long COVID (x axis)

and for *FOXP4* expression in the lung (y axis), regional association of the *FOXP4* locus variants with long COVID (top right) and regional association of the *FOXP4* variants with RNA expression measured in the lung in GTEx (bottom right). Variants are colored by 1000 Genomes European-ancestry LD r^2 with the lead variant (**rs12660421**) for *FOXP4* expression in lung tissue (the most significant long COVID variant overlapping the GTEx v8 dataset (**rs9381074**) also annotated). **c**, Human Protein Atlas RNA single-cell type tissue cluster data (transcript expression levels summarized per gene and cluster) of lung (GSE130148) showing *FOXP4* expression in unaffected individuals. The values were visualized using $\log_{10}(\text{pTPM} + 1)$ values. Each annotation is taken from the clustering results performed in the Human Protein Atlas. pTPM, protein transcripts per million.

Furthermore, variants in the *FOXP4* region have also been identified as risk factors for COVID-19 hospitalization, colocalizing with *FOXP4* expression eQTL in the COVID-19 HGI meta-analyses and follow-up studies^{16,24} (Supplementary Fig. 8 and Supplementary Table 18). Our colocalization analysis demonstrated the *FOXP4* association identified here as the same association identified for COVID-19 severity (posterior probability > 0.97 ; Supplementary Fig. 7e,f and Supplementary Table 17).

***FOXP4* expression in blood is associated with long COVID**

To understand whether higher *FOXP4* expression was seen in long COVID, we collected blood samples from participants with or without active SARS-CoV-2 infection. We discovered that the higher *FOXP4* levels in nonacute COVID-19 samples were associated with increased risk of long COVID (OR = 2.31 per 1 s.d. increase in *FOXP4* expression, 95% CI = 1.27–4.22, $P = 0.0063$; Supplementary Fig. 9), while *FOXP4* levels in acute COVID-19 samples were not associated with long COVID

($P = 0.62$). This is orthogonal evidence to the genetic signal that higher *FOXP4* levels may lead to long COVID.

***FOXP4* expression in alveolar and immune cells in the lung**

As lung tissue consists of several cell types, we wanted to elucidate the relevant cells that express *FOXP4* and may contribute to long COVID. We analyzed single-cell sequencing data from the Tabula Sapiens, a previously published atlas of single-cell sequencing data in healthy individuals free of COVID-19²⁵. *FOXP4* expression was the highest in type 2 alveolar cells in individuals without SARS-CoV-2 infection (Fig. 4c) and during active infection (Supplementary Fig. 10), suggesting that SARS-CoV-2 infection was not required for *FOXP4* expression. Furthermore, type 2 alveolar cells are capable of mounting robust innate immune responses, thus participating in the immune regulation in the lung. Additionally, type 2 alveolar cells secrete surfactant, keep the alveoli free from fluid, and serve as progenitor cells repopulating damaged epithelium after injury²⁶. In addition, we observed nearly equally

high expression of *FOXP4* in granulocytes that similarly participate in the regulation of innate immune responses. Overall, the findings suggest a possible role of both immune and alveolar cells in the lung and higher expression of *FOXP4* in long COVID.

***FOXP4* variants located at active chromatin in the lung**

To understand the possible causal variation at the *FOXP4* locus, we performed statistical fine mapping using SLALOM²⁷ (Supplementary Note). There were nine variants within the 95% credible set with the maximum posterior probability of 0.28 for rs9381074 (Supplementary Fig. 11). Given the strong LD pattern among the nine variants within the credible set, fine mapping alone might not be able to pinpoint a single causal variant in this locus. Therefore, to understand possible functional regulatory effects behind the variant association, we used the data from the Regulome database^{28,29}, ENCODE³⁰ and VannoPortal³¹. While the majority of the long COVID variants were at active enhancer or transcription factor binding sites, four variants had direct evidence of transcription factor binding based on chromatin immunoprecipitation sequencing experiments (Supplementary Tables 19 and 20). One of these variants (rs9381074) was directly located on a region that had DNA methylation marks across multiple tissues, including immune and lung cells (H3K27me3 and H3K4me1, H3K4me3, H3K27ac, H3K4me2 and H3K4me3), and had evidence of transcriptional activity from 49 different transcription factors, of which we saw the most consistent direct binding of FOXA1 across 55 experiments. Furthermore, we downloaded DNase sequencing data from the ENCODE project and observed that rs9381074 was directly positioned on a DNase hypersensitivity site in the lung (Supplementary Note). Finally, this variant is the same variant implicated by statistical fine mapping, suggesting the rs9381074 variant as the causal variant for association at the *FOXP4* locus.

***FOXP4* variant associated with lung cancer**

To understand the role of *FOXP4* and its associations across diseases, we performed genome-wide association analysis. We first focused on Biobank Japan³², as the long COVID risk allele frequency is highest in East Asia. Genome-wide association study (PheWAS) between rs9367106 and all phenotypes in Biobank Japan ($n = 262$) revealed that long COVID risk allele was associated with lung cancer ($P = 1.2 \times 10^{-6}$, Bonferroni $P = 3.1 \times 10^{-4}$, OR = 1.13, 95% CI = 1.07–1.18; Supplementary Fig. 8 and Supplementary Table 18). Furthermore, the long COVID risk allele is in LD with the known risk variants for non-small cell lung carcinoma in Chinese and European populations³³ (rs1853837, $r^2 = 0.88$ in East Asians³⁴) and for lung cancer in never-smoking Asian women³⁵ (rs7741164, $r^2 = 0.98$ in East Asians³⁴). Colocalization analysis supported that the associations in this locus (within 500 kb of rs9367106) for long COVID and lung cancer shared the same genetic signal (colocalization posterior probability = 0.98; Supplementary Fig. 7c,d). COVID-19 phenotypes and lung cancer traits were the only associations found with linked variants in the GWAS Catalog (Supplementary Table 21).

We then broadened the analysis to other cohorts. Using data from FinnGen and Open Targets, we observed a robust gene level PheWAS association with prostate cancer, immune traits including reticulocytes and chronotype (Supplementary Tables 22–24). Moreover, colocalization analysis provided by Open Targets showed that *FOXP4* expression and *FOXP4* splice QTLs colocalized with blood count traits specifically in the blood and the thyroid, but the blood count traits did not colocalize with the expression in the lung (Supplementary Table 25). These findings suggest that separate regulatory variation may contribute to tissue-specific expression and the control of otherwise ubiquitously expressed *FOXP4* and contribute to trait associations in a tissue-specific manner.

Long COVID and other phenotypes

We investigated the relationship between long COVID and cardiometabolic, behavioral and psychiatric traits³⁶ (Fig. 5 and Supplementary

Table 26). We found positive genetic correlations between long COVID and insomnia symptoms, depression, risk tolerance, asthma, diabetes and SARS-CoV-2 infection, while we saw negative correlations with red and white blood cell counts (Fig. 5a). However, identified correlations were only nominally significant without multiple testing correction ($P < 0.05$; Supplementary Table 27). The observed scale heritability estimates of long COVID ranged from 0.97% to 12.36% (s.e. = 0.0362), with the highest heritability in the strict case and strict control definitions (Supplementary Table 28).

We used Mendelian randomization (MR) to estimate potential risk factors by analyzing the same traits mentioned above (Supplementary Table 26). Genetically predicted earlier smoking initiation ($P = 0.022$), more cigarettes consumed per day ($P = 0.046$), higher levels of high-density lipoproteins ($P = 0.029$) and higher body mass index ($P = 0.046$) were nominally significant causal risk factors of long COVID (Fig. 5b and Supplementary Table 29). However, none of these associations survived correction for multiple comparisons.

***FOXP4* signal not explained simply by COVID-19 severity**

Earlier research has suggested that COVID-19 severity is a risk factor for long COVID^{8,37–39} and *FOXP4* variants have earlier been implicated in COVID-19 severity⁶. Our initial GWAS and robust replication across different cohorts show *FOXP4* variants also associated with long COVID. However, the results pose an interesting question of whether the mechanism of *FOXP4* association with long COVID is the same mechanism that contributes to COVID-19 severity. We thus investigated the relationship between COVID-19 hospitalization and long COVID by performing a two-sample MR (Supplementary Table 30). In terms of causality, we caution that COVID-19 hospitalization as causal exposure is difficult to interpret because both long COVID and COVID-19 hospitalization are two outcomes of the same underlying infection. Nevertheless, the relationship between the effect size for long COVID versus the effect size for COVID-19 severity can shed some light on the role of COVID-19 severity in long COVID. To perform two-sample MR without overlapping samples, we have excluded the studies that contributed to the current long COVID freeze 4 and computed a meta-analysis of SARS-CoV-2 infection susceptibility and COVID-19 hospitalization of the remaining cohorts in the COVID-19 HGI. We observed a causal relationship of susceptibility and hospitalization on long COVID (strict case and broad control definition; inverse variance-weighted (IVW) MR, $P = 1.8 \times 10^{-7}$ for infection and $P = 4.8 \times 10^{-8}$ for hospitalization) with no evidence of pleiotropy (MR-Egger intercept $P = 0.47$ and 0.83, respectively; Fig. 5c,d and Supplementary Table 30). Furthermore, sensitivity analysis by leaving one variant out (Supplementary Table 31), or by including long COVID cohorts with European ancestry only (Supplementary Table 32), both supported a robust causal association between COVID hospitalization and long COVID. Nevertheless, the Wald ratio of long COVID to COVID-19 hospitalization for the *FOXP4* variant is 1.97 (95% CI = 1.36–2.57), which is significantly greater than the slope of the MR-estimated relationship between COVID-19 hospitalization and long COVID (0.35, 95% CI = 0.12–0.57). Furthermore, adjusting or stratifying the long COVID GWAS for hospitalization did not explain the association between *FOXP4* and long COVID (Supplementary Table 33a).

Thus, the *FOXP4* signal demonstrates a stronger association with long COVID than expected, meaning that it cannot simply be explained by its association with either susceptibility or severity of the acute disease alone (Fig. 5c,d). A recent systematic review of epidemiological data found a positive association between COVID-19 hospitalization and long COVID with a relationship on a log-odds scale of 0.91 (95% CI = 0.68–1.14)⁴⁰. Even assuming this stronger relationship between COVID-19 hospitalization and long COVID, the observed effect of the *FOXP4* variant on long COVID still exceeds what would be expected based on the association with severity alone.




Fig. 5 | Genetic correlations and MR causal estimates between long COVID and potential risk factors, biomarkers and diseases. a, b, LD score regression (a, LDSC, top; Supplementary Table 27) and IVW MR (b, fixed-effects model, bottom; Supplementary Table 29 and Supplementary Data) were used for calculating two-sided P values. The size of each colored square corresponds to statistical significance (*** $P < 0.0001$, full-sized square; ** $P < 0.01$, full-sized square; * $P < 0.05$, full-sized square; $P < 0.1$, large square; $P < 0.5$, medium square and $P > 0.5$, small square; not corrected for multiple comparisons). A full list of traits is provided in Supplementary Table 26. For sample sizes in each long COVID GWAS meta-analysis using strict (S) or broad (B) case and control definitions, see Supplementary Table 11. c, MR scatter plot with effect sizes ($\beta \pm$ s.e.) of each variant on COVID-19 susceptibility (reported SARS-CoV-2 infection) as exposure and long COVID (strict case, broad control definition) as outcome (P (IVW, fixed effects) = 1.8×10^{-7} , pleiotropy $P = 0.47$; Supplementary Table 30). d, Similarly, MR

with COVID-19 hospitalization as exposure and long COVID as outcome (P (IVW fixed effects) = 4.8×10^{-8} , pleiotropy $P = 0.83$; Supplementary Table 30). e, Analysis of shared and unique effects between SARS-CoV-2 infection susceptibility and long COVID using a Bayesian mixture model showed ABO and 3p21.31 rs73062389 as having shared effects (posterior probability > 0.99). FOXP4 variant association was discovered in the long COVID meta-analyses but showed also an effect on the susceptibility of the initial infection, though smaller than on long COVID (Supplementary Table 34). (Effects shown as β , error bars represent 95% confidence intervals.) f, Similarly, analysis of shared and unique effects between COVID-19 severity and long COVID using a Bayesian mixture model showed FOXP4 variant with a joint effect (posterior probability > 0.9), differing from the other severity variants due to its larger effect on long COVID (Supplementary Table 35). BMI, body mass index; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; ADHD, attention-deficit hyperactivity disorder.

When SARS-CoV-2 infection is required for COVID-19 disease, and for severe COVID-19, an important question is whether all genetic variants that increase COVID-19 susceptibility or severity are equally large risk factors for long COVID. Bayesian methods provide an opportunity to estimate whether some variants that affect COVID-19 susceptibility or severity systematically contribute to the risk of long COVID more than the other variants. To answer this question, we estimated the posterior probabilities for all susceptibility and severity variants for long COVID using four models—susceptibility/severity only, long COVID only and two models for joint effects that differed in their slopes. We observed that for COVID-19 susceptibility, the 3p21.31 locus and the *ABO* locus contributed to both susceptibility and long COVID with a high posterior probability (Fig. 5e and Supplementary Table 34). Moreover, while many severity variants are also likely to contribute to long COVID, their slope between long COVID and severity effects was smaller than that of *FOXP4* (Fig. 5f and Supplementary Table 35).

Finally, previous studies have shown a potential effect of vaccination, strain and severity on long COVID^{5,7,41–44}. To clarify these factors with long COVID, we used data from additional cohorts, including FinnGen. We observed that, while adjusting for severity or vaccination status did not remove the signal, there was a possible stronger risk of *FOXP4* risk alleles before vaccination and with wild-type and Alpha strains (Supplementary Table 33b,c). A significant association of the *FOXP4* locus with long COVID in individuals before vaccination was observed. Although the effect remained positive postvaccination (OR = 1.3), the lack of significant association in these cases may be influenced by the relatively small sample size of individuals diagnosed with long COVID after vaccination ($n = 40$; Supplementary Table 33b). Earlier epidemiological studies have shown that immunization against COVID-19 is associated with a reduced risk of long COVID^{43–45}. Our data are in line with these earlier observations. Furthermore, we sought replication for the strain association in the Estonian Biobank, where higher risk was also observed with earlier strains, particularly the Alpha strain ($P = 0.0138$).

The possible time-dependent association with strain prompted us to explore the temporal relationship between *FOXP4* and long COVID from the start of the year 2020 till the spring of 2023. Using data from 3,684 individuals with long COVID from FinnGen, we observed a significant temporal association with the Cox proportional hazards model (HR = 1.3, 95% CI = 1.1–1.7, $P = 0.005$, $n_{\text{population controls}} = 496,664$; Supplementary Fig. 12). Moreover, particularly homozygosity for the *FOXP4* risk allele increased the risk for long COVID (recessive $P = 2.3 \times 10^{-4}$, OR = 5.64, 95% CI = 2.25–14.17). Moreover, we observed a consistently higher risk allele homozygosity among long COVID cases in the Estonian Biobank and MexGene-COVID (Supplementary Note). Overall, these results indicate a temporal relationship with *FOXP4* risk variants on long COVID and higher risk with homozygosity and earlier viral strains. In all these analyses, *FOXP4* stood out as an independent risk factor for long COVID.

***FOXP4* associates with multiple symptoms of long COVID**

We aimed to investigate the symptomatic associations between *FOXP4* and long COVID. We focused on well-established components of long COVID as documented in earlier literature⁷. Using symptom data from the two largest cohorts, FinnGen and MVP, we re-examined the association of *FOXP4* with long COVID, requiring lifetime symptoms from any of the previously identified subtypes. Our analysis revealed consistent associations across both MVP and FinnGen cohorts, with fatigue and asthma diagnoses, and β -adrenergic and proton pump inhibitor medication showing significant associations in the meta-analysis of the two cohorts (Supplementary Fig. 13 and Supplementary Table 36). The replication of these associations in datasets from two different countries, with distinct healthcare settings and patient populations, strengthens the robustness of the link between *FOXP4* and the plethora of manifestations of long COVID.

Discussion

In this study, we aimed to understand the host genetic factors that contribute to long COVID, using data from 24 studies across 16 countries and replicating in independent cohorts. Our analysis identified genetic variants within the *FOXP4* locus as a risk factor for long COVID. The *FOXP4* gene is expressed in the lung and the genetic variants associated with long COVID are also associated with differential expression of *FOXP4* and with lung cancer and COVID-19 severity. Additionally, using MR, we characterized COVID-19 severity as a causal risk factor for long COVID. Overall, our findings provide genomic evidence consistent with previous epidemiological and clinical reports of long COVID, indicating that long COVID, similarly to other postviral conditions, is a heterogeneous disease entity where likely both individual genetic variants and the environmental risk factors contribute to disease risk.

Our analysis revealed a connection between long COVID and pulmonary endpoints through both individual variants at *FOXP4*, a transcription factor-coding gene previously linked to lung cancer and COVID-19 severity²⁴, and MR analysis identifying smoking and COVID-19 severity as risk factors. Furthermore, expression analysis of the lung, and cell type-specific single-cell sequencing analysis, showed *FOXP4* expression in both alveolar cell types and immune cells of the lung.

FOXP4 belongs to the subfamily P of the forkhead box transcription factor family genes and is expressed in various tissues, including the lungs and the gut^{45,46}. Moreover, it is highly expressed in mucus-secreting cells of the stomach and intestines⁴⁷, as well as in naïve B, natural killer and memory T_{reg} cells⁴⁸, and required for normal T cell memory function following infection⁴⁹. *FOXP1/FOXP2/FOXP4* are also required for promoting lung endoderm development by repressing expression of nonpulmonary transcription factors⁵⁰, and the loss of *FOXP1/FOXP4* adversely affects airway epithelial regeneration⁵¹. Furthermore, *FOXP4* has been implicated in airway fibrosis⁵² and the promotion of lung cancer growth and invasion⁵³. We find that the variants associated with long COVID are also associated with lung cancer in Biobank Japan³². These observations together with the present study may suggest that the connection between *FOXP4* and long COVID may be rooted in both lung function and immunology. Furthermore, *FOXP4* expression in both alveolar and immune cells in the lung, and the association with severe COVID-19 and pulmonary diseases such as cancer, suggests that *FOXP4* may participate in local immune responses in the lung.

Our functional analysis further implicated *FOXP4* as a risk factor for long COVID, irrespective of the genotype status of the here-identified risk variant. *FOXP4* expression levels were higher in individuals with long COVID than controls. Furthermore, we observed a consistent effect of *FOXP4* risk variants across ancestries. Moreover, having multiple ancestries enabled us to fine-map a likely causal variant at rs9381074, which was further supported by functional methylation and expression data.

We also discovered a causal relationship between SARS-CoV-2 infection and long COVID, as expected, and an additional causal risk between severe, hospital treatment-requiring COVID-19 and long COVID. This finding is in agreement with earlier epidemiological observations^{8,37–39}. The relationship between COVID-19 severity and long COVID raises an interesting question—when SARS-CoV-2 infection is required for both COVID-19 and severe COVID-19, are all genetic variants that increase COVID-19 susceptibility or severity equally large risk factors for long COVID? In the present study, we aimed to answer this question by examining variant effect sizes between SARS-CoV-2 infection susceptibility, COVID-19 severity and long COVID using stratified and adjusted analyses, and by Bayesian modeling. Among the known SARS-CoV-2 susceptibility loci, *ABO* and 3p21.31 had a high probability of also contributing to long COVID. Moreover, the *FOXP4* variants had higher effect sizes for long COVID than expected based on the other severity variants, suggesting an independent role of *FOXP4* for long

COVID that was not observed among the other COVID-19 severity variants. Such observation offers clues on biological mechanisms, such as *FOXP4* affecting pulmonary function and immunity, which then contribute to the development of long COVID. Overall, our study elucidates genetic risk factors for long COVID, the relationship between long COVID and severe COVID-19, and finally possible mechanisms of how *FOXP4* contributes to the risk of long COVID.

Moreover, while several lines of evidence from the original GWAS association, replication, stratified analyses to Bayesian analysis and the significance of individual variants suggest that *FOXP4* contributes to long COVID in a stronger way than expected, the mechanism that *FOXP4* associates with long COVID may be the same mechanism that contributes to COVID-19 severity. Future studies and iterations of this work will likely grow the number of observed genetic variants and further clarify the biological mechanisms underlying long COVID. We also caution that the genetic predisposition to long COVID might be dependent on SARS-CoV-2 variation and vaccination status, and that a large portion of our data was collected before the omicron wave and widespread vaccination (Supplementary Table 12), which might have an impact on the genetic associations.

The contribution of genetic factors to COVID-19 phenotypes is intriguing. As heritability in general is defined as the proportion of phenotypic variation attributable to genetic differences within a specific environment, in a hypothetical world where every environmental factor would be similar, heritability would theoretically approach 100%. However, as the heritability in infections can be shaped by exposure, viral strain, prophylactics, earlier immunity, for example, through vaccination efforts, or differences in diagnostic criteria, reporting or local recommendations, estimating heritability requires relatively large samples for precise estimates. Similarly, heritability in earlier studies of COVID-19 phenotypes was initially less than 1% for COVID-19 susceptibility, severity and critical illness even with over 46,000 COVID-19 cases and 2 million controls⁶. However, all COVID-19 traits showed robust genetic correlations with the known COVID-19 epidemiological risk factors. In our study, we similarly see low heritability with long COVID, which is a limitation in the current study. Nonetheless, the estimate provides a tool to understand between-trait correlations and will likely become more precise with larger sample sizes.

We recognize that the symptomatology of long COVID is variable and includes, in addition to lung symptoms, also other symptom domains such as fatigue and cognitive dysfunction^{7,37,54}. In addition, the long-term effects of COVID-19 are still being studied, and more research is needed to understand the full extent of the long-term damage caused by SARS-CoV-2 and long COVID disease. We also recognize that the long COVID diagnosis is still evolving. Nevertheless, our study provides direct genetic evidence that lung pathophysiology can have an integral part in the development of long COVID.

Online content

Any methods, additional references, Nature Portfolio reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at <https://doi.org/10.1038/s41588-025-02100-w>.

References

- Soriano, J. B., Murthy, S., Marshall, J. C., Relan, P. & Diaz, J. V. A clinical case definition of post-COVID-19 condition by a Delphi consensus. *Lancet Infect. Dis.* **22**, e102–e107 (2022).
- Desai, A. D., Lavelle, M., Boursiquot, B. C. & Wan, E. Y. Long-term complications of COVID-19. *Am. J. Physiol. Cell Physiol.* **322**, C1–C11 (2022).
- Mehandru, S. & Merad, M. Pathological sequelae of long-haul COVID. *Nat. Immunol.* **23**, 194–202 (2022).
- Hugon, J., Msika, E.-F., Queneau, M., Farid, K. & Paquet, C. Long COVID: cognitive complaints (brain fog) and dysfunction of the cingulate cortex. *J. Neurol.* **269**, 44–46 (2022).
- Ceban, F. et al. Fatigue and cognitive impairment in post-COVID-19 syndrome: a systematic review and meta-analysis. *Brain Behav. Immun.* **101**, 93–135 (2022).
- Sykes, D. L. et al. Post-COVID-19 symptom burden: what is long-COVID and how should we manage it? *Lung* **199**, 113–119 (2021).
- Davis, H. E., McCorkell, L., Vogel, J. M. & Topol, E. J. Long COVID: major findings, mechanisms and recommendations. *Nat. Rev. Microbiol.* **21**, 133–146 (2023).
- Global Burden of Disease Long COVID Collaborators. et al. Estimated global proportions of individuals with persistent fatigue, cognitive, and respiratory symptom clusters following symptomatic COVID-19 in 2020 and 2021. *JAMA* **328**, 1604–1615 (2022).
- Mizrahi, B. et al. Long COVID outcomes at one year after mild SARS-CoV-2 infection: nationwide cohort study. *BMJ* **380**, e072529 (2023).
- Wong, A. C. et al. Serotonin reduction in post-acute sequelae of viral infection. *Cell* **186**, 4851–4867 (2023).
- Appelman, B. et al. Muscle abnormalities worsen after post-exertional malaise in long COVID. *Nat. Commun.* **15**, 17 (2024).
- Cervia-Hasler, C. et al. Persistent complement dysregulation with signs of thromboinflammation in active long COVID. *Science* **383**, eadg7942 (2024).
- The COVID-19 Host Genetics Initiative The COVID-19 Host Genetics Initiative, a global initiative to elucidate the role of host genetic factors in susceptibility and severity of the SARS-CoV-2 virus pandemic. *Eur. J. Hum. Genet.* **28**, 715–718 (2020).
- Nakanishi, T. et al. Age-dependent impact of the major common genetic risk factor for COVID-19 on severity and mortality. *J. Clin. Invest.* **131**, e152386 (2021).
- Kanai, M. et al. A second update on mapping the human genetic architecture of COVID-19. *Nature* **621**, E7–E26 (2023).
- COVID-19 Host Genetics Initiative Mapping the human genetic architecture of COVID-19. *Nature* **600**, 472–477 (2021).
- Ellinghaus, D. et al. Genomewide association study of severe COVID-19 with respiratory failure. *N. Engl. J. Med.* **383**, 1522–1534 (2020).
- Pairo-Castineira, E. et al. Genetic mechanisms of critical illness in COVID-19. *Nature* **591**, 92–98 (2021).
- Bergström, A. et al. Insights into human genetic variation and population history from 929 diverse genomes. *Science* **367**, eaay5012 (2020).
- Auton, A. et al. A global reference for human genetic variation. *Nature* **526**, 68–74 (2015).
- Lek, M. et al. Analysis of protein-coding genetic variation in 60,706 humans. *Nature* **536**, 285–291 (2016).
- GTEX Consortium The Genotype-Tissue Expression (GTEx) project. *Nat. Genet.* **45**, 580–585 (2013).
- GTEX Consortium The GTEx Consortium atlas of genetic regulatory effects across human tissues. *Science* **369**, 1318–1330 (2020).
- D’Antonio, M. et al. SARS-CoV-2 susceptibility and COVID-19 disease severity are associated with genetic variants affecting gene expression in a variety of tissues. *Cell Rep.* **37**, 110020 (2021).
- Tabula Sapiens Consortium The Tabula Sapiens: a multiple-organ, single-cell transcriptomic atlas of humans. *Science* **376**, eabl4896 (2022).
- Mason, R. J. Biology of alveolar type II cells. *Respirology* **11**, S12–S15 (2006).

27. Kanai, M. et al. Meta-analysis fine-mapping is often miscalibrated at single-variant resolution. *Cell Genom.* **2**, 100210 (2022).
28. Boyle, A. P. et al. Annotation of functional variation in personal genomes using RegulomeDB. *Genome Res.* **22**, 1790–1797 (2012).
29. Dong, S. et al. Annotating and prioritizing human non-coding variants with RegulomeDB v.2. *Nat. Genet.* **55**, 724–726 (2023).
30. ENCODE Project Consortium An integrated encyclopedia of DNA elements in the human genome *Nature* **489**, 57–74 (2012).
31. Huang, D. et al. VannoPortal: multiscale functional annotation of human genetic variants for interrogating molecular mechanism of traits and diseases. *Nucleic Acids Res.* **50**, D1408–D1416 (2022).
32. Nagai, A. et al. Overview of the BioBank Japan Project: study design and profile. *J. Epidemiol.* **27**, S2–S8 (2017).
33. Dai, J. et al. Identification of risk loci and a polygenic risk score for lung cancer: a large-scale prospective cohort study in Chinese populations. *Lancet Respir. Med.* **7**, 881–891 (2019).
34. Machiela, M. J. & Chanock, S. J. LDlink: a web-based application for exploring population-specific haplotype structure and linking correlated alleles of possible functional variants. *Bioinformatics* **31**, 3555–3557 (2015).
35. Wang, Z. et al. Meta-analysis of genome-wide association studies identifies multiple lung cancer susceptibility loci in never-smoking Asian women. *Hum. Mol. Genet.* **25**, 620–629 (2016).
36. COVID-19 Host Genetics Initiative A first update on mapping the human genetic architecture of COVID-19. *Nature* **608**, E1–E10 (2022).
37. Sudre, C. H. et al. Attributes and predictors of long COVID. *Nat. Med.* **27**, 626–631 (2021).
38. Subramanian, A. et al. Symptoms and risk factors for long COVID in non-hospitalized adults. *Nat. Med.* **28**, 1706–1714 (2022).
39. Resendez, S. et al. Defining the subtypes of long COVID and risk factors for prolonged disease: population-based case-crossover study. *JMIR Public Health Surveill.* **10**, e49841 (2024).
40. Tsampasian, V. et al. Risk factors associated with post-COVID-19 condition: a systematic review and meta-analysis. *JAMA Intern. Med.* **183**, 566–580 (2023).
41. Al-Aly, Z., Bowe, B. & Xie, Y. Long COVID after breakthrough SARS-CoV-2 infection. *Nat. Med.* **28**, 1461–1467 (2022).
42. Antonelli, M. et al. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study. *Lancet Infect. Dis.* **22**, 43–55 (2022).
43. Ayoubkhani, D. et al. Trajectory of long covid symptoms after covid-19 vaccination: community based cohort study. *BMJ* **377**, e069676 (2022).
44. Du, M., Ma, Y., Deng, J., Liu, M. & Liu, J. Comparison of long COVID-19 caused by different SARS-CoV-2 strains: a systematic review and meta-analysis. *Int. J. Environ. Res. Public Health* **19**, 16010 (2022).
45. Lu, M. M., Li, S., Yang, H. & Morrissey, E. E. Foxp4: a novel member of the Foxp subfamily of winged-helix genes co-expressed with Foxp1 and Foxp2 in pulmonary and gut tissues. *Mech. Dev.* **119**, S197–S202 (2002).
46. Takahashi, K., Liu, F.-C., Hirokawa, K. & Takahashi, H. Expression of Foxp4 in the developing and adult rat forebrain. *J. Neurosci. Res.* **86**, 3106–3116 (2008).
47. Uhlén, M. et al. Proteomics. Tissue-based map of the human proteome. *Science* **347**, 1260419 (2015).
48. Schmiedel, B. J. et al. Impact of genetic polymorphisms on human immune cell gene expression. *Cell* **175**, 1701–1715.e16 (2018).
49. Wiehagen, K. R. et al. Foxp4 is dispensable for T cell development, but required for robust recall responses. *PLoS ONE* **7**, e42273 (2012).
50. Li, S. et al. Foxp transcription factors suppress a non-pulmonary gene expression program to permit proper lung development. *Dev. Biol.* **416**, 338–346 (2016).
51. Li, S. et al. Foxp1/4 control epithelial cell fate during lung development and regeneration through regulation of anterior gradient 2. *Development* **139**, 2500–2509 (2012).
52. Chen, Y. et al. Downregulation of microRNA-423-5p suppresses TGF- β 1-induced EMT by targeting FOXP4 in airway fibrosis. *Mol. Med. Rep.* **26**, 242 (2022).
53. Yang, T. et al. FOXP4 modulates tumor growth and independently associates with miR-138 in non-small cell lung cancer cells. *Tumour Biol.* **36**, 8185–8191 (2015).
54. Castaneres-Zapatero, D. et al. Pathophysiology and mechanism of long COVID: a comprehensive review. *Ann. Med.* **54**, 1473–1487 (2022).
55. Karczewski, K. J. et al. The mutational constraint spectrum quantified from variation in 141,456 humans. *Nature* **581**, 434–443 (2020).
56. Cunningham, F. et al. Ensembl 2022. *Nucleic Acids Res.* **50**, D988–D995 (2022).

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2025

Vilma Lammi^{1,210}, **Tomoko Nakanishi**^{1,2,3,4,5,6,210}, **Samuel E. Jones**^{1,210}, **Shea J. Andrews**⁷, **Juha Karjalainen**^{1,8,9,10}, **Beatriz Cortés**^{11,12}, **Heath E. O'Brien**¹³, **Ana Ochoa-Guzman**¹⁴, **Brian E. Fulton-Howard**¹⁵, **Martin Broberg**¹, **Hele H. Haapaniemi**¹, **Masahiro Kanai**^{16,17}, **Matti Pirinen**^{1,18,19}, **Axel Schmidt**²⁰, **Ruth E. Mitchell**^{21,22}, **Abdou Mousas**²³, **Massimo Mangino**²⁴, **Alicia Huerta-Chagoya**^{25,26,27,28}, **Nasa Sinnott-Armstrong**^{29,30,31}, **Elizabeth T. Cirulli**³², **Marc Vaudel**^{33,34,35}, **Alex S. F. Kwong**³⁶, **Amit K. Maiti**³⁷, **Minttu M. Marttila**^{38,39}, **Daniel C. Posner**⁴⁰, **Alexis A. Rodriguez**⁴¹, **Chiara Batini**^{42,43}, **Francesca Minnai**^{44,45}, **Anna R. Dearman**⁴⁶, **C. A. Robert Warmerdam**^{47,48}, **Celia B. Sequeros**⁴⁹, **Thomas W. Winkler**⁵⁰, **Daniel M. Jordan**^{51,52}, **Raimonds Rešcenko**⁵³, **Lorenzo Miano**⁵⁴, **Jacqueline M. Lane**^{55,56,57}, **Ryan K. Chung**⁵⁸, **Beatriz Guillen-Guio**^{42,59}, **Olivia C. Leavy**^{42,59}, **Laura Carvajal-Silva**⁶⁰, **Kevin Aguilar-Valdés**⁶⁰, **Erika Frangione**⁶¹, **Lindsay Guare**⁶², **Ekaterina Vergasova**⁶³, **Eirini Marouli**⁶⁴, **Pasquale Striano**⁶⁵, **Ummu Afeera Zainulabid**⁶⁶, **Ashutosh Kumar**⁶⁷, **Hajar Fauzan Ahmad**⁶⁸, **Ryuya Edahiro**^{69,70},

Shuhei Azekawa^{1,72}, Long COVID Host Genetics Initiative*, FinnGen*, VA Million Veteran Program*, MexGen-COVID Initiative*, DBDS Genomic Consortium*, GEN-COVID Multicenter Study*, PHOSP-COVID Collaborative Group*, GENCOV Study*, Estonian Biobank Research Team*, Shih-Wen Luoh^{73,74}, Christian Erikstrup⁷⁵, Ole B. V. Pedersen⁷⁶, Jordan Lerner-Ellis^{61,77,78}, Alicia Colombo^{60,79,80}, Joseph J. Grzymalski⁸¹, Makoto Ishii^{71,72}, Yukinori Okada^{5,69,82,83}, Noam D. Beckmann^{51,84}, Meena Kumari⁴⁶, Ralf Wagner^{85,86}, Iris M. Heid⁵⁰, Catherine John^{42,87}, Patrick J. Short¹³, Per Magnus⁸⁸, Laura Ansone⁵³, Luca V. C. Valenti^{89,90}, Sulggi A. Lee⁹¹, Louise V. Wain^{42,59}, Ricardo A. Verdugo^{60,92}, Karina Banasik⁴⁹, Frank Geller⁹³, Lude H. Franke^{47,48}, Alexander Rakitko⁶³, Emma L. Duncan^{94,95}, Alessandra Renieri^{96,97,98}, Konstantinos K. Tsilidis^{23,99}, Rafael de Cid^{11,12}, Ahmadreza Niavarani¹⁰⁰, Erik Abner¹⁰¹, Teresa Tusié-Luna^{102,103}, Shefali S. Verma⁶², George Davey Smith^{21,22}, Nicholas J. Timpson^{21,22}, Ravi K. Madduri¹⁰⁴, Kelly Cho¹⁰⁵, Mark J. Daly^{1,16,17}, Andrea Ganna^{1,16,17}, Eva C. Schulte^{106,107,108,109,110}, J. Brent Richards^{2,3,24,111,112}, Kerstin U. Ludwig²⁰, Michael Marks-Hultström^{112,113,114}, Hugo Zeberg^{115,116,211} ✉ & Hanna M. Ollila^{1,117,118,119,211} ✉

¹Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland. ²Department of Human Genetics, McGill University, Montreal, Quebec, Canada. ³Centre for Clinical Epidemiology, Department of Medicine, Lady Davis Institute, Jewish General Hospital, McGill University, Montreal, Quebec, Canada. ⁴Kyoto-McGill International Collaborative Program in Genomic Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan. ⁵Department of Genome Informatics, Graduate School of Medicine, the University of Tokyo, Tokyo, Japan. ⁶Research Fellow, Japan Society for the Promotion of Science, Tokyo, Japan. ⁷Department of Psychiatry and Behavioral Sciences, University of California San Francisco, San Francisco, CA, USA. ⁸Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, MA, USA. ⁹Stanley Center for Psychiatric Research, Broad Institute of Harvard and MIT, Cambridge, MA, USA. ¹⁰Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, MA, USA. ¹¹Genomes for Life-GCAT Lab, CORE Program, Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain. ¹²Grup de Recerca en Impacte de les Malalties Cròniques i les seves Trajectòries (GRIMTra), Barcelona, Spain. ¹³Sano Genetics Limited, London, UK. ¹⁴Unidad de Biología Molecular y Medicina Genómica, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico. ¹⁵Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York City, NY, USA. ¹⁶Broad Institute, Cambridge, MA, USA. ¹⁷Analytical and Translational Genetics Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. ¹⁸Department of Mathematics and Statistics, University of Helsinki, Helsinki, Finland. ¹⁹Department of Public Health, University of Helsinki, Helsinki, Finland. ²⁰Institute of Human Genetics, University of Bonn, School of Medicine and University Hospital Bonn, Bonn, Germany. ²¹MRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK. ²²Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK. ²³Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece. ²⁴Department of Twin Research, King's College London, London, UK. ²⁵Program in Metabolism and Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA. ²⁶Center for Genomic Medicine and Diabetes Unit, Endocrine Division, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA. ²⁷Departamento de Medicina Genómica y Toxicología Ambiental, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Mexico City, Mexico. ²⁸Unidad de Biología Molecular y Medicina Genómica, Instituto Nacional de Ciencias Médicas y Nutrición, Mexico City, Mexico. ²⁹Herbold Computational Biology Program, Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, USA. ³⁰Department of Genome Sciences, University of Washington, Seattle, WA, USA. ³¹Finnish Institute of Molecular Medicine, University of Helsinki, Helsinki, Finland. ³²Helix, San Mateo, CA, USA. ³³Mohn Center for Diabetes Precision Medicine, Department of Clinical Science, University of Bergen, Bergen, Norway. ³⁴Department of Genetics and Bioinformatics, Health Data and Digitalization, Norwegian Institute of Public Health, Oslo, Norway. ³⁵Computational Biology Unit, Department of Informatics, University of Bergen, Bergen, Norway. ³⁶Centre for Clinical Brain Sciences, Division of Psychiatry, University of Edinburgh, Edinburgh, UK. ³⁷Department of Genetics and Genomics, Myndavar, Southfield, MI, USA. ³⁸University of Helsinki, Helsinki, Finland. ³⁹Helsinki University Central Hospital, Helsinki, Finland. ⁴⁰VA Boston Healthcare System, Boston, MA, USA. ⁴¹Data Science and Learning, Argonne National Laboratory, Lemont, IL, USA. ⁴²Department of Population Health Sciences, University of Leicester, Leicester, UK. ⁴³University Hospitals of Leicester NHS Trust, Leicester, UK. ⁴⁴Institute for Biomedical Technologies—National Research Council, Segrate, Italy. ⁴⁵Department of Medical Biotechnology and Translational Medicine (BioMeTra), Università degli Studi di Milano, Milan, Italy. ⁴⁶Institute for Social and Economic Research, University of Essex, Colchester, UK. ⁴⁷Department of Genetics, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands. ⁴⁸Onco Investigator, Utrecht, the Netherlands. ⁴⁹Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. ⁵⁰Department of Genetic Epidemiology, University of Regensburg, Regensburg, Germany. ⁵¹Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York City, NY, USA. ⁵²Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York City, NY, USA. ⁵³Latvian Biomedical Research and Study Centre, Riga, Latvia. ⁵⁴Università degli Studi di Milano, Milan, Italy. ⁵⁵Brigham and Women's Hospital Division of Sleep and Circadian Disorders, Boston, MA, USA. ⁵⁶Massachusetts General Hospital, Center for Genomic Medicine, Boston, MA, USA. ⁵⁷Broad Institute, Molecular and Population Genetics Program, Cambridge, MA, USA. ⁵⁸Center for Computational Biology, University of California Berkeley, Berkeley, CA, USA. ⁵⁹The Institute for Lung Health, NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, UK. ⁶⁰Departamento de Oncología Básica Clínica, Facultad de Medicina, Universidad de Chile, Santiago, Chile. ⁶¹Mount Sinai Hospital, Sinai Health, Toronto, Ontario, Canada. ⁶²Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA. ⁶³Genotek Ltd, Moscow, Russia. ⁶⁴William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK. ⁶⁵IRCCS G Gaslini, Genoa, Italy. ⁶⁶Department of Internal Medicine, Kuliyah of Medicine, International Islamic University Malaysia, Pahang, Malaysia. ⁶⁷Department of Anatomy, All India Institute of Medical Sciences—Patna, Patna, India. ⁶⁸Faculty of Industrial Sciences and Technology, Universiti Malaysia Pahang Al Sultan Abdullah, Pahang, Malaysia. ⁶⁹Department of Statistical Genetics, Osaka University Graduate School of Medicine, Suita, Japan. ⁷⁰Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, Suita, Japan. ⁷¹Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan. ⁷²Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan. ⁷³VA Portland Health Care System, Portland, Portland, OR, USA. ⁷⁴Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA. ⁷⁵Department of Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark. ⁷⁶Department of Clinical Immunology, Zealand University Hospital—Køge, Køge, Denmark. ⁷⁷University of Toronto, Toronto, Ontario, Canada.

⁷⁸Lunenfeld-Tanenbaum Research Institute, Sinai Health, Toronto, Ontario, Canada. ⁷⁹Departamento de Anatomía Patológica, Facultad de Medicina, Universidad de Chile, Santiago, Chile. ⁸⁰Servicio de Anatomía Patológica, Hospital Clínico de la Universidad de Chile, Santiago, Chile. ⁸¹Department of Internal Medicine, University of Nevada Reno, School of Medicine, Reno, NV, USA. ⁸²Laboratory for Systems Genetics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan. ⁸³Laboratory of Statistical Immunology, Immunology Frontier Research Center (WPI-IFReC), Osaka University, Suita, Japan. ⁸⁴Division of Data Driven Medicine, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York City, NY, USA. ⁸⁵Institute of Medical Microbiology and Hygiene, Molecular Microbiology (Virology), University of Regensburg, Regensburg, Germany. ⁸⁶Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, Regensburg, Germany. ⁸⁷Leicester National Institute for Health and Care Research, Biomedical Research Centre, Glenfield Hospital, Leicester, UK. ⁸⁸Centre for Fertility and Health, Norwegian Institute of Public Health, Oslo, Norway. ⁸⁹Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy. ⁹⁰Biological Resource Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. ⁹¹Department of Medicine, Division of HIV, Infectious Diseases and Global Medicine, University of California, San Francisco, CA, USA. ⁹²Instituto de Investigación Interdisciplinaria y Facultad de Medicina, Universidad de Talca, Talca, Chile. ⁹³Statens Serum Institute, Copenhagen, Denmark. ⁹⁴Department of Endocrinology, Guy's and St Thomas' NHS Foundation Trust, London, UK. ⁹⁵Department of Twin Research and Genetic Epidemiology, King's College London, London, UK. ⁹⁶Medical Genetics, University of Siena, Siena, Italy. ⁹⁷Med Biotech Hub and Competence Center, Department of Medical Biotechnologies, University of Siena, Siena, Italy. ⁹⁸Genetica Medica, Azienda Ospedaliero-Universitaria Senese, Siena, Italy. ⁹⁹Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK. ¹⁰⁰Digestive Oncology Research Center, Digestive Disease Research Institute, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran. ¹⁰¹Estonian Genome Center, Institute of Genomics, University of Tartu, Tartu, Estonia. ¹⁰²Instituto de Investigaciones Biomédicas, UNAM, Mexico City, Mexico. ¹⁰³Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico. ¹⁰⁴Data Science and Learning Division, Argonne National Laboratory, Lemont, IL, USA. ¹⁰⁵Department of Medicine, Harvard Medical School and Mass General Brigham, Boston, MA, USA. ¹⁰⁶Department of Psychiatry, University of Munich, Munich, Germany. ¹⁰⁷Institute of Human Genetics, University Hospital, Faculty of Medicine, University of Bonn, Bonn, Germany. ¹⁰⁸Institute of Virology, Technical University of Munich/Helmholtz Munich, Munich, Germany. ¹⁰⁹Institute of Psychiatric Phenomics and Genomics, University of Munich, Munich, Germany. ¹¹⁰Department of Psychiatry, University Hospital, Faculty of Medicine, University of Bonn, Bonn, Germany. ¹¹¹Prime Sciences Inc, Montreal, Quebec, Canada. ¹¹²Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec, Canada. ¹¹³Lady Davis Institute of Medical Research, Jewish General Hospital, McGill University, Montreal, Quebec, Canada. ¹¹⁴Anaesthesiology and Intensive Care Medicine, Department of Surgical Sciences, Uppsala University, Uppsala, Sweden. ¹¹⁵Department of Evolutionary Genetics, Max Planck Institute for Evolutionary Anthropology, Leipzig, Germany. ¹¹⁶Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden. ¹¹⁷Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA. ¹¹⁸Anesthesia, Critical Care, and Pain Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. ¹¹⁹Broad Institute of MIT and Harvard, Cambridge, MA, USA. ¹²⁰These authors contributed equally: Vilma Lammi, Tomoko Nakanishi, Samuel E. Jones. ¹²¹These authors jointly supervised this work: Hugo Zeberg, Hanna M. Ollila. *Lists of authors and their affiliations appear at the end of the paper. ✉e-mail: hugo.zeberg@ki.se; hanna.m.ollila@helsinki.fi

Long COVID Host Genetics Initiative

Vilma Lammi^{1,210}, Tomoko Nakanishi^{1,2,3,4,5,6,210}, Samuel E. Jones^{1,210}, Hugo Zeberg^{115,116,211}, Hanna M. Ollila^{1,117,118,119,211}, Shea J. Andrews⁷, Juha Karjalainen^{1,8,9,10}, Brian E. Fulton-Howard¹⁵, Amit K. Maiti³⁷, Minttu M. Marttila^{38,39}, Eirini Marouli⁶⁴, Pasquale Striano⁶⁵, Ummu Afeera Zainulabid⁶⁶, Ashutosh Kumar⁶⁷ & Hajar Fauzan Ahmad⁶⁸

Lists of members and their affiliations appears in the Supplementary Information.

FinnGen

Vilma Lammi^{1,210}, Samuel E. Jones^{1,210}, Hanna M. Ollila^{1,117,118,119,211}, Martin Broberg¹, Hele H. Haapaniemi¹, Matti Pirinen^{1,18,19}, Nasa Sinnott-Armstrong^{29,30,31}, Mark J. Daly^{1,16,17}, Andrea Ganna^{1,16,17}, Mari E. K. Niemi^{1,18,19}, Masahiro Kanai^{1,16,17}, Avon Longitudinal Study of Parents and Children (ALSPAC), Banque québécoise de la COVID-19 (BQC19) & Bonn Study of COVID Genetics (BoSCO)

Avon Longitudinal Study of Parents and Children (ALSPAC)

Ruth E. Mitchell^{21,22}, Alex S.F. Kwong³⁶, George Davey Smith^{21,22} & Nicholas J. Timpson^{21,22}

Banque québécoise de la COVID-19 (BQC19)

Tomoko Nakanishi^{1,2,3,4,5,6,210}, J. Brent Richards^{2,3,24,111,112}, Janick St-Cyr¹²⁰, Darin Adra¹²¹, Madeleine Durand^{122,123}, David Bujold¹²⁰, Guillaume Bourque¹²⁰, Ariane Boisclair¹²⁰, Mylene Bertrand¹²⁴, Daniel Auld¹²⁰, Laetitia Laurent¹²¹, Solomia Yanishevsky¹²⁰, G. Mark Lathrop¹²⁰, Fangyi Shi¹²¹, Simon Rousseau¹²⁵, Jiannis Ragoussis¹²⁰, Danielle Perley¹²⁰, Vincent Mosser¹²⁰ & David R. Morrison¹²¹

Bonn Study of COVID Genetics (BoSCO)

Axel Schmidt²⁰, Kerstin U. Ludwig²⁰, Daniella Balla²⁰, Julia Heggemann²⁰, Sonja Schultz²⁰, Pari Behzad²⁰, Markus M. Nöthen²⁰, Abigail Miller²⁰, Max C. Pensel¹²⁶ & Carlo Maj¹²⁷

¹²⁰Victor Phillip Dahdaleh Institute of Genomic Medicine at McGill University and Department of Human Genetics, McGill University, Montreal, Quebec, Canada. ¹²¹Lady Davis Institute, Jewish General Hospital, McGill University, Montreal, Quebec, Canada. ¹²²Research Centre of the Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, Quebec, Canada. ¹²³Centre hospitalier de l'Université de Montréal (CHUM), Montreal, Quebec, Canada. ¹²⁴Institut universitaire de cardiologie et de pneumologie de Québec, Université Laval, Quebec, Quebec, Canada. ¹²⁵The Meakins-Christie Laboratories at the Research Institute of the McGill University Health, Centre Research Institute, and Department of Medicine, Faculty of Medicine, McGill University, Montreal, Quebec, Canada. ¹²⁶Department of Psychiatry and Psychotherapy, University of Bonn, Bonn, Germany. ¹²⁷Center for Human Genetics, University Hospital of Marburg, Marburg, Germany. Lists of members and their affiliations appears in the Supplementary Information.

VA Million Veteran Program

Daniel C. Posner⁴⁰, Alexis A. Rodriguez⁴¹, Shih-Wen Luoh^{73,74}, Ravi K. Madduri¹⁰⁴, Kelly Cho^{73,105}, Tianxi Cai¹²⁸ & Sudha K. Iyengar^{129,130}

¹²⁸Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA. ¹²⁹Louis Stokes Cleveland VA Medical Center, Cleveland, Ohio, USA. ¹³⁰Department of Population and Quantitative Health Sciences, Case Western Reserve University, Cleveland, OH, USA. Lists of members and their affiliations appears in the Supplementary Information.

MexGen-COVID Initiative

Teresa Tusié-Luna^{102,103}, Ana Ochoa-Guzman¹⁴, Alicia Huerta-Chagoya^{25,26,27,28}, Carlos A. Aguilar Salinas¹³¹, Seung Hyuk T. Lee¹³², Hortensia Moreno-Macias¹³³, Päivi Pajukanta^{132,134} & Michelle Duran-Gomez¹⁴, Norwegian Mother Father and Child Cohort Study (MoBa), Penn Medicine BioBank (PMBB), Follow-UP study of patients with critical COVID-19 (SweCovid) and COVID-19 Cohort Study of the University Hospital of the Technical University Munich (Muenchen rechts der Isar) (COMRI), Tirschenreuth Study (TiKoCo) TwinsUK, UK Biobank (UKB), UnderstandingSociety: UK Household Longitudinal Study, COVID-19 Genomics Network (C19-GenoNet) & COVID-19 Host Immune Response Pathogenesis Study (CHIRP)

Norwegian Mother Father and Child Cohort Study (MoBa)

Marc Vaudel^{33,34,35}, Per Magnus⁸⁸ & Lill Trogstad¹³⁵

Penn Medicine BioBank (PMBB)

Lindsay Guare⁶², Shefali S. Verma⁶², Daniel J. Rader¹³⁶, Marylyn D. Ritchie¹³⁷, Anurag Verma¹³⁸ & Colleen M. Kripke¹³⁸

Follow-UP study of patients with critical COVID-19 (SweCovid) and COVID-19 Cohort Study of the University Hospital of the Technical University Munich (Muenchen rechts der Isar) (COMRI)

Eva C. Schulte^{106,107,108,109,110}, Michael Marks-Hultström^{112,113,114}, Hugo Zeberg^{115,116,211}, Sergi Papiol^{139,140}, Jens Wiltfang^{141,142,143}, Jochen Schneider¹⁴⁴, Thomas G. Schulze^{139,145,146,147}, Christof Winter^{148,149}, Ewa Wallin¹¹⁴, Robert Frithiof¹¹⁴, Fanny Senner¹³⁹, Christoph D. Spinner¹⁴⁴, Ulrike Protzer^{108,150}, Mattia Cordoli¹, Nikola S. Mueller¹⁵¹, Andreas Dinkel¹⁵², Janos L. Kalman^{139,153}, Tomislav Maricic¹¹⁵, Kristina Adorjan^{154,155}, Miklos Lipcsey¹¹⁴, Lisa Fricke¹⁵⁶, Ing-Marie Larsson¹¹⁴, Urs Heilbronner¹³⁹, Monika Budde¹³⁹ & Johanna Erber¹⁴⁴

Tirschenreuth Study (TiKoCo)

Thomas W. Winkler⁵⁰, Ralf Wagner^{85,86} & Iris M. Heid⁵⁰

TwinsUK

Massimo Mangino²⁴, Emma L. Duncan^{94,95} & Nicholas R. Harvey¹⁵⁷

UK Biobank (UKB)

Tomoko Nakanishi^{11,2,3,4,5,6,210}, J. Brent Richards^{2,3,24,111,112} & Vince Forgetta¹¹¹

UnderstandingSociety: UK Household Longitudinal Study

Anna R. Dearman⁴⁶, Meena Kumari⁴⁶ & Benedict Hignell⁴⁶

COVID-19 Genomics Network (C19-GenoNet)

Ricardo A. Verdugo^{60,92}, Laura Carvajal-Silva⁶⁰, Kevin Aguilar-Valdés⁶⁰, Alicia Colombo^{60,79,80}, Yolanda Espinosa-Parrilla^{158,159,160}, Juan M. Saez Hidalgo¹⁶¹, Estefania Nova-Lamperti¹⁶², Scarlett Gutiérrez-Richards¹⁶³, Gerardo Donoso¹⁶⁴, Leslie C. Cerpa⁶⁰, Cesar A. Echeverria¹⁶⁵, Camilo Cabrera¹⁶², Pamela Bocchieri¹⁶², Macarena Fuentes-Guajardo¹⁶⁶, Christian A. Muñoz¹⁶³, Karen Y. Oróstica¹⁶⁷, Alvaro Figueroa¹⁶⁸, Lissette G. Guajardo¹⁶⁹, Iskra A. Signore^{79,170}, Virginia A. Monardes-Ramírez¹⁷¹, Eduardo A. Tobar-Calfucoy¹⁷², Luis A. Quiñones¹⁷³, Cristian E. Yáñez¹⁷², Daniela Zapata-Contreras^{158,159}, Paula Zuñiga-Pacheco^{158,159}, Romina Quiroga¹⁶², Matías F. Martínez¹⁷⁴, Teresa A. Alarcon¹⁶⁹, Andrea X. Silva^{175,176}, Carolina S. Selman¹⁶⁹, Sergio Sanhuesa¹⁶², Rocío Retamales-Ortega¹⁷², Tamara V. Arévalo⁶⁰, Eduardo Lamoza⁶⁰ & Héctor Valenzuela-Jorquera¹⁶⁸

COVID-19 Host Immune Response Pathogenesis Study (CHIRP)

Ryan K. Chung⁵⁸, Sulggi A. Lee⁹¹, Maria Sophia Donaire⁹¹ & Sannidhi Sarvadhavabhatla⁹¹

¹³¹Instituto Nacional de Ciencias Medicas y Nutricion, Ciudad de México, Mexico. ¹³²Department of Human Genetics, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. ¹³³Universidad Autonoma Metropolitana, Mexico City, Mexico. ¹³⁴Institute for Precision Health, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. ¹³⁵Division of Infection Control, Norwegian Institute of Public Health, Oslo, Norway. ¹³⁶Department of Medicine,

Department of Genetics, Division of Translational Medicine and Human Genetics, Institute for Translational Medicine and Therapeutics, University of Pennsylvania, Philadelphia, PA, USA. ¹³⁷Department of Genetics, University of Pennsylvania, Philadelphia, PA, USA. ¹³⁸Department of Medicine, Division of Translational Medicine and Human Genetics, Institute for Translational Medicine and Therapeutics, University of Pennsylvania, Philadelphia, PA, USA. ¹³⁹Institute of Psychiatric Phenomics and Genomics (IPPG), University Hospital, LMU Munich, Munich, Germany. ¹⁴⁰Max-Planck Institute of Psychiatry, Munich, Germany. ¹⁴¹Department of Psychiatry and Psychotherapy, University Medical Center Goettingen, Goettingen, Germany. ¹⁴²German Center for Neurodegenerative Diseases (DZNE), Goettingen, Germany. ¹⁴³Neurosciences and Signaling Group, Institute of Biomedicine (iBiMED), Department of Medical Sciences, University of Aveiro, Aveiro, Portugal. ¹⁴⁴Department of Internal Medicine II, University Hospital rechts der Isar, Technical University of Munich, School of Medicine, Munich, Germany. ¹⁴⁵Department of Psychiatry and Behavioral Sciences, Johns Hopkins University, Baltimore, MD, USA. ¹⁴⁶Department of Psychiatry and Behavioral Sciences, SUNY Upstate Medical University, Syracuse, NY, USA. ¹⁴⁷Department of Genetic Epidemiology in Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany. ¹⁴⁸Institute of Clinical Chemistry and Pathobiochemistry, Klinikum rechts der Isar, School of Medicine, Technical University of Munich, Munich, Germany. ¹⁴⁹TranslaTUM, Center for Translational Cancer Research, Technical University of Munich, Munich, Germany. ¹⁵⁰German Center for Infection Research (DZIF), Munich Site, Braunschweig, Germany. ¹⁵¹Institute of Computational Biology, Helmholtz Center Munich, Oberschleissheim, Germany. ¹⁵²Department of Psychosomatic Medicine and Psychotherapy, Klinikum rechts der Isar, School of Medicine, Technical University of Munich, Munich, Germany. ¹⁵³Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich, Germany. ¹⁵⁴Institute of Psychiatric Phenomics and Genomics (IPPG), LMU University Hospital, LMU Munich, Munich, Germany. ¹⁵⁵Department of Psychiatry and Psychotherapy, University of Bern, Bern, Switzerland. ¹⁵⁶Department of Internal Medicine II, Klinikum Rechts der Isar, School of Medicine, Technical University of Munich, Munich, Germany. ¹⁵⁷Department of Twin Research and Epidemiology, King's College London, London, UK. ¹⁵⁸Genómica Evolutiva y Médica de Magallanes (GEMMa), Centro Asistencial, Docente e Investigación (CADI-UMAG), Punta Arenas, Chile. ¹⁵⁹Escuela de Medicina, Universidad de Magallanes, Punta Arenas, Chile. ¹⁶⁰Interuniversity Center for Healthy Aging, Santiago, Chile. ¹⁶¹Departamento de Ciencias de la Computación, Facultad de Ciencias Físicas y Matemáticas, Universidad de Chile, Santiago, Chile. ¹⁶²Molecular and Translational Immunology Laboratory, Department of Clinical Biochemistry and Immunology, Pharmacy Faculty, University of Concepción, Concepción, Chile. ¹⁶³Departamento de Tecnología Médica, Facultad de Ciencias de la Salud, Universidad de Antofagasta, Antofagasta, Chile. ¹⁶⁴Servicio de Anatomía, Hospital Clínico de la Universidad de Chile, Santiago, Chile. ¹⁶⁵ATACAMA OMICS, Laboratorio de Biología Molecular y Genómica, Facultad de Medicina, Universidad de Atacama, Copiapó, Chile. ¹⁶⁶Departamento de Tecnología Médica, Universidad de Tarapacá, Arica, Chile. ¹⁶⁷Instituto de Investigación Interdisciplinaria y Escuela de Medicina, Universidad de Talca, Talca, Chile. ¹⁶⁸AUSTRAL-omics, Vicerrectoría de Investigación Desarrollo y Creación Artística, Universidad Austral de Chile, Valdivia, Chile. ¹⁶⁹Unidades de Diagnóstico Fundación Arturo López Pérez, Providencia, Chile. ¹⁷⁰Facultad de Medicina, Universidad de Atacama, Copiapó, Chile. ¹⁷¹Laboratorio Clínico del Área Técnica de Biología Molecular, Hospital del Salvador, Santiago, Chile. ¹⁷²Programa de Genética Humana del Instituto de Ciencias Biomédicas (ICBM), Facultad de Medicina, Universidad de Chile, Santiago, Chile. ¹⁷³Departamento de Oncología Básico Clínica, Facultad de Medicina and Departamento de Ciencias y Tecnología Farmacéutica, Universidad de Chile, Santiago, Chile. ¹⁷⁴Departamento de Ciencias y Tecnología Farmacéutica, Universidad de Chile, Santiago, Chile. ¹⁷⁵AUSTRAL-omics, Vicerrectoría de Investigación Desarrollo y Creación Artística, Valdivia, Chile. ¹⁷⁶Instituto de Ciencias Ambientales y Evolutivas, Facultad de Ciencias, Universidad Austral de Chile, Valdivia, Chile. Lists of members and their affiliations appears in the Supplementary Information.

DBDS Genomic Consortium

Celia B. Sequeros⁴⁹, Christian Erikstrup⁷⁵, Ole B. V. Pedersen⁷⁶, Karina Banasik⁴⁹, Frank Geller⁹³, Sisse R. Ostrowski¹⁷⁷, Søren Brunak⁴⁹, David Westergaard⁴⁹, Bjarke Feenstra⁹³, Anne Sofie B. Mortensen¹⁷⁸ & Extended Cohort for E-health, Environment and DNA (EXCEED), Genomes for Life (GCAT) and Cohort COVID in Catalonia (COVICAT study) & Genomes for Life (GCAT) and Cohort COVID in Catalonia (COVICAT study)

Extended Cohort for E-health, Environment and DNA (EXCEED)

Chiara Batini^{42,43}, Louise V. Wain^{42,59}, Catherine John^{42,87} & Anna L. Guyatt^{42,87}

Genomes for Life (GCAT) and Cohort COVID in Catalonia (COVICAT study)

Rafael de Cid^{11,12}, Beatriz Cortés^{11,12}, Susana Iraola-Guzmán^{11,12}, Gemma Moncunill^{179,180}, Alba Blasco^{181,182,183}, Judith Garcia-Aymerich^{184,185}, Natalia Blay^{11,12}, Carlota Dobaño^{179,180}, Anna Carreras^{181,182,183}, Xavier Farré^{11,12}, Manolis Kogevinas^{184,185,186,187} & Gemma Castaño-Vinyals^{184,185,186}

¹⁷⁷Department of Clinical Immunology, Copenhagen University Hospital—Rigshospitalet, Copenhagen, Denmark. ¹⁷⁸Department of Medical Endocrinology and Metabolism, Copenhagen University Hospital (Rigshospitalet), Copenhagen, Denmark. ¹⁷⁹ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Spain. ¹⁸⁰CIBER de Enfermedades Infecciosas (CIBERINFEC), Barcelona, Spain. ¹⁸¹Genomes for Life-GCAT lab, Barcelona, Spain. ¹⁸²Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain. ¹⁸³Grup de REcerca en Impacte de les Malalties Cròniques i les seves Trajectòries (GRIMTra), (2021 SGR 01537), Badalona, Spain. ¹⁸⁴ISGlobal, Barcelona, Spain. ¹⁸⁵Universitat Pompeu Fabra (UPF), Barcelona, Spain. ¹⁸⁶CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain. ¹⁸⁷IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain. Lists of members and their affiliations appears in the Supplementary Information.

GEN-COVID Multicenter Study

Francesca Minnai^{44,45}, Alessandra Renieri^{96,97,98}, Simone Furini¹⁸⁸, Chiara Fallerin^{189,190}, Kristina Zguro¹⁹¹, Margherita Baldassarri^{96,97,98}, Francesca Colombo¹⁹² & Genetics of Long Covid (GOLD), Genotek, Helix-Helix Exome+ and Healthy Nevada Project COVID-19 Phenotypes, Covid-19 Ioannina Biobank, Genome-wide assessment of the gene variants associated with severe COVID-19 phenotype in Iran (IrCovid), Japan COVID-19 Task Force, Lifelines, Lifelines & Mount Sinai COVID Biobank (MSCIC)

Genetics of Long Covid (GOLD)

Heath E. O'Brien¹³, Patrick J. Short¹³ & Thompson Hannah¹³

Genotek

Alexander Rakitko⁶³, Ekaterina Vergasova⁶³, Anna Ilinskaya¹⁹³, Michil Trofimov⁶³, Layal Shaheen⁶³, Nikolay Plotnikov⁶³, Anna Kim⁶³, Dmitrii Kharitonov⁶³, Valery Ilinsky¹⁹³ & Alexei Kamelin⁶³

Helix–Helix Exome+ and Healthy Nevada Project COVID-19 Phenotypes

Elizabeth T. Cirulli³², Joseph J. Grzymski⁸¹, Francisco Tanudjaja³², Efren Sandoval³², Nicole L. Washington³², Simon White³², Iva Neveux¹⁹⁴, Shaun Dabe¹⁹⁵, Alexandre Bolze³² & Kelly M. Schiabor Barrett³²

Covid-19 Ioannina Biobank

Abdou Mousas²³, Konstantinos K. Tsilidis^{23,99}, Eirini Christaki¹⁹⁶, Haralampos Milionis¹⁹⁶, Ioanna Tzoulaki¹⁹⁷, Angelos Lontos¹⁹⁶, Evangelos Evangelou^{23,99} & Evangelia Ntzani^{23,198}

Genome-wide assessment of the gene variants associated with severe COVID-19 phenotype in Iran (IrCovid)

Ahmadreza Niavarani¹⁰⁰, Rasoul Aliannejad¹⁹⁹, Vahideh Zarei²⁰⁰, Nastaran Soltani²⁰¹, Bahareh Sharififard¹⁰⁰, Hengameh Ansari Tadi²⁰¹ & Ali Amirsavadkouhi²⁰²

Japan COVID-19 Task Force

Ryuya Eda^{69,70}, Shuhei Azekawa^{71,72}, Makoto Ishii^{71,72}, Yukinori Okada^{5,69,82,83}, Ho NamKoong²⁰³ & Masahiro Kanai^{16,17}

Lifelines

C. A. Robert Warmerdam^{47,48} & Lude H. Franke^{47,48}

Mount Sinai COVID Biobank (MSCIC)

Daniel M. Jordan^{51,52}, Noam D. Beckmann^{51,84}, Ryan C. Thompson^{51,52}, Alexander W. Charney^{51,204}, Laura G. Sloofman^{51,52} & Nicole W. Simons^{51,52}

¹⁸⁸Department of Electrical, Electronic and Information Engineering ‘Guglielmo Marconi’, University of Bologna, Cesena, Italy. ¹⁸⁹Department of Medical Biotechnologies, Med Biotech Hub and Competence Center, University of Siena, Siena, Italy. ¹⁹⁰Medical Genetics Unit, University of Siena, Policlinico Le Scotte, Siena, Italy. ¹⁹¹Med Biotech Hub and Competence Centre, Department of Medical Biotechnologies, University of Siena, Siena, Italy. ¹⁹²Institute for Biomedical Technologies, National Research Council, Segrate, Italy. ¹⁹³Eligens SIA, Riga, Latvia. ¹⁹⁴University of Nevada, School of Medicine, Reno, NV, USA. ¹⁹⁵Renown Health, Reno, NV, USA. ¹⁹⁶First Department of Internal Medicine and Infectious Diseases Unit, University Hospital of Ioannina, Ioannina, Greece. ¹⁹⁷Biomedical Research Foundation Academy of Athens, Athens, Greece. ¹⁹⁸Center for Evidence-Based Medicine, Department of Health Services, Policy and Practice, School of Public Health, Brown University, Providence, RI, USA. ¹⁹⁹Department of Pulmonary and Critical Care, School of Medicine, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran. ²⁰⁰General Intensive Care Unit, Department of Anesthesiology, School of Medicine, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran. ²⁰¹Intensive Care Unit, Department of Emergency, School of Medicine, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran. ²⁰²Department of Critical Care Medicine, Noorafshar Hospital, Tehran, Iran. ²⁰³Department of Infectious Diseases, Keio University School of Medicine, Tokyo, Japan. ²⁰⁴Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York City, NY, USA. Lists of members and their affiliations appears in the Supplementary Information.

PHOSP-COVID Collaborative Group

Beatriz Guillen-Guio^{42,59}, Olivia C. Leavy^{42,59} & Louise V. Wain^{42,59}

GENCOV Study

Erika Frangione⁶¹, Jordan Lerner-Ellis^{61,77,78}, Olga Vishnyakova²⁰⁵, Xu Xinyi⁶¹, Jennifer Taher^{61,77}, Lloyd T. Elliott²⁰⁵ & Genome Database of the Latvian Population (LGDB) & MassGeneralBrigham (MGB)

Genome Database of the Latvian Population (LGDB)

Raimonds Rešcenko⁵³, Laura Ansone⁵³, Vita Rovite⁵³, Peculis Raitis⁵³, Monta Briviba⁵³ & Janis Klovins⁵³

MassGeneralBrigham (MGB)

Jacqueline M. Lane^{55,56,57}, Richa Saxena^{117,118,119}, Angus C. Burns²⁰⁶, Jakob M. Cherry⁵⁵, Matthew Maher^{117,118,119} & Hanna M. Ollila^{1,117,118,119,211}

²⁰⁵Simon Fraser University, Burnaby, British Columbia, Canada. ²⁰⁶Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.

Estonian Biobank Research Team

Erik Abner¹⁰¹ & Arne Kukkonen¹⁰¹ & Fondazione COVID-19 Genomic Study (FOGS)

Fondazione COVID-19 Genomic Study (FOGS)

Lorenzo Miano⁵⁴, Luca V. C. Valenti^{89,90}, Mauro Tettamanti²⁰⁷, Luisa Ronzoni²⁰⁸, Daniele Prati²⁰⁸, Flora Peyvandi^{54,208}, Rossana Carpani²⁰⁸, Antonio Muscatello²⁰⁸, Sara Margarita²⁰⁸, Francesco Malvestiti⁵⁴, Giuseppe Lamorte²⁰⁸, Marco Mantero²⁰⁸, Andre Franke²⁰⁹, David Ellinghaus²⁰⁹, Nathalie Iannotti²⁰⁸, Nicola Montano⁵⁴, Alessandro Nobili²⁰⁷, Frauke Degenhardt²⁰⁹, Alessandra Bandera^{54,208}, Fabio Blandini²⁰⁸, Francesco Bruno Arturo Blasi^{54,208} & Tom Hemming Karlsen⁹⁴

²⁰⁷Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy. ²⁰⁸Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.

²⁰⁹University of Oslo, Oslo, Norway.

Methods

Contributing studies

Participants of each of the contributing 33 studies provided written informed consent to participate in each respective study, with recruitment and ethics following study-specific protocols approved by their respective institutional review boards (details are provided in Supplementary Table 12).

For the initial discovery analysis, we used data from the following 24 studies: Avon Longitudinal Study of Parents and Children (ALSPAC), Bonn Study of COVID Genetics (BoSCO), Banque québécoise de la COVID-19 (BQC19), Danish Blood Donor Study (DBDS), Extended Cohort for E-health, Environment and DNA (EXCEED), FinnGen, GCAT | Genomes for life, Genetic Bases of COVID-19 Clinical Variability (GEN-COVID), Genotek, Genetics of Long COVID (GOLD), Helix Exome+ and Healthy Nevada Project COVID-19 Phenotypes (Helix), MexGen-COVID Initiative, COVID-19 Ioannina Biobank (Ioannina), Genome-wide assessment of the gene variants associated with severe COVID-19 phenotype in Iran (IrCovid), Japan COVID-19 Task Force (JapanTaskForce), Lifelines, Norwegian Mother, Father and Child Cohort Study (MoBa), Mount Sinai COVID Biobank (MSCIC), Penn Medicine BioBank (PMBB), Follow-UP study of patients with critical COVID-19/COVID-19 Cohort Study of the University Hospital of the Technical University Munich (SweCovid/COMRI), Tirschenreuth Study (TiKoCo), TwinsUK, UK Biobank and Understanding Society—UK Household Longitudinal Study. The total sample size of this Long COVID HGI data freeze 4 was 6,450 long COVID cases, 46,208 COVID-19-positive controls and 1,093,955 population controls (Supplementary Table 12). For the replication of the *FOXP4* lead variants, we obtained data from the following nine additional studies: COVID-19 cohort at LGDB (LatviaGDB), COVID-19 Genomics Network (C19-GenoNet), COVID-19 Host Immune Response Pathogenesis Study (CHIRP), Estonian Biobank (EstBB), Fondazione Genomics SARS-CoV-2 Study (FoGS), GENCOV Study (GENCOV), Mass General Brigham Biobank (MGB), The Post-hospitalization COVID-19 study (PHOSP-COVID) and VA MVP. The replication datasets together comprised 9,500 individuals with long COVID and 798,835 population controls (Supplementary Fig. 3d,e and Supplementary Table 12).

The effective sample sizes for each study shown in Fig. 1 were calculated for display using the given formula: $(4 \times n_{\text{case}} \times n_{\text{control}}) / (n_{\text{case}} + n_{\text{control}})$. The Long COVID HGI is a global and ongoing collaboration, open to all studies around the world that have data to run long COVID GWAS using our phenotypic criteria described below.

Phenotype definitions

We used the following criteria for assigning case–control status for long COVID aligning with the World Health Organization guidelines¹ (Supplementary Note; https://github.com/long-covid-hg/LongCovidTools/blob/main/PhenotypeDefinitions_LongCOVID_v1.docx). Study participants were defined as long COVID cases if, at least three months since SARS-CoV-2 infection or COVID-19 onset, they met any of the following criteria:

1. Presence of one or more self-reported COVID-19 symptoms that cannot be explained by an alternative diagnosis
2. Report of ongoing substantial impact on day-to-day activities
3. Any diagnosis codes of long COVID (for example, post-COVID-19 condition, ICD-10 code U09(.9))

Criteria 1 and 2 were applied only to questionnaire-based cohorts, whereas 3 was used in studies with electronic health records (EHR). Detailed phenotyping criteria and diagnosis codes of each study are provided in Supplementary Table 12.

We used two long COVID case definitions, a strict definition requiring a test-verified SARS-CoV-2 infection and a broad definition including self-reported or clinician-diagnosed SARS-CoV-2 infection (any long COVID).

We applied two control definitions. First, we used population controls, that is, everybody that is not the case. Population controls were genetic ancestry-matched individuals who were not defined as long COVID cases using the above-mentioned questionnaire or EHR-based definition. In the second analysis, we compared long COVID cases to individuals who had had SARS-CoV-2 infection but who did not meet the criteria of long COVID, that is, had fully recovered within three months from the infection.

We used in total four different case–control definitions to generate four GWASs as below:

1. Long COVID cases after test-verified SARS-CoV-2 infection versus population controls (the strict case definition versus the broad control definition)
2. Long COVID within test-verified SARS-CoV-2 infection (the strict case definition versus the strict control definition)
3. Any long COVID cases versus population controls (the broad case definition versus the broad control definition)
4. Long COVID within any SARS-CoV-2 infection (the broad case definition versus the strict control definition)

To further investigate the effect of *FOXP4* locus on the different manifestations of long COVID⁷ in the FinnGen and MVP datasets, we used combined criteria of any long COVID diagnosis (BB: ICD-10 diagnosis code: U09* (where * can be empty or any string, referring to sub-diagnoses)) with lifetime occurrence of specific symptom diagnoses: diabetes (ICD-10: E10*, E11*, E12*, E13*, E14*), fatigue and malaise (ICD-10: R53*, G93.3), asthma (ICD-10: J45*), skin paresthesia (ICD-10: R20.2), β -adrenergic inhalants (Anatomical Therapeutic Chemical (ATC) drug code: R03AC*), headache (ICD-10: R51*), proton pump inhibitors (ATC: A02BC*) or cardiac arrhythmia/abnormalities of heartbeat (ICD-10: I49*, R00*; Supplementary Fig. 13 and Supplementary Table 36). The effect of the risk variant [rs9367106-C](#) on long COVID with each symptom or medication was estimated separately using logistic regression, adjusting for age, sex and ten principal components. Finnish ancestry from FinnGen and African, Admixed American and European ancestries from the MVP were first analyzed separately, followed by a meta-analysis and test for heterogeneity.

GWAS

We largely applied the GWAS analysis plans used in the COVID-19 HGI⁶. Each study performed its own sample collection, genotyping, genotype and sample quality control, imputation and association analyses independently, according to our central analysis plan (https://github.com/long-covid-hg/LongCovidTools/blob/main/COVID19HostGenetics_AnalysisPlan_LongCOVID_v1.docx), before submitting the GWAS summary statistic level results for meta-analysis (details are provided in Supplementary Table 12). We recommended that GWASs were run using REGENIE⁵⁷ on chromosomes 1–22 and X, although a minority of the contributing studies used SAIGE⁵⁸ or PLINK2 (ref. 59; Supplementary Table 12). The minimum set of covariates to be included at runtime were age, age², sex, age $\times$ sex and the first ten genetic principal components. We advised studies to include any additional study-specific covariates where needed, such as those related to genotype batches or other demographic and technical factors that could lead to stratification within the cohort. Studies ($n = 2$) performing the GWAS using software that does not account for sample relatedness (such as PLINK) were advised to exclude related individuals.

GWAS meta-analyses

The meta-analysis pipeline was also adopted from the COVID-19 HGI flagship paper¹⁶. The code is available at Long COVID HGI GitHub (https://github.com/long-covid-hg/META_ANALYSIS/) and is a modified version of the pipeline developed for the COVID-19 HGI (https://github.com/covid19-hg/META_ANALYSIS). To ensure that individual

study results did not suffer from excessive inflation, deflation and false positives, we manually investigated plots of the reported allele frequencies against aggregated gnomAD v3.0 (ref. 55) allele frequencies in the same population. We also evaluated whether the association standard errors were excessively small, given the calculated effective sample size, to identify studies deviating from the expected trend. Where these issues were detected, the studies were contacted to reperform the association analysis, if needed, and resubmit their results.

Before the meta-analysis itself, the summary statistics were standardized, filtered (excluding variants with allele frequency <0.1% or imputation INFO score <0.6), lifted over to reference genome build GRCh38 (in studies imputed to GRCh37) and harmonized to gnomAD v3.0 through matching by chromosome, position and alleles (Supplementary Note).

The meta-analysis was performed using a fixed-effects IVW method on variants that were present in at least two studies contributing to the specific phenotype being analyzed. To assess whether one study was primarily driving any associations, we simultaneously ran a leave-most-significant-study-out (LMSSO) meta-analysis for each variant (based on the variant's study-level *P* value). Heterogeneity between studies was estimated using Cochran's *Q* test⁶⁰. Each set of meta-analysis results was then filtered to exclude variants whose total effective sample size (in the non-LMSSO analysis) was less than one-third of the total effective sample size of all studies contributing to that meta-analysis. We report significant loci that pass the genome-wide significance threshold ($P \leq 5 \times 10^{-8}/4 = 1.25 \times 10^{-8}$) accounting for the number of GWAS meta-analyses we performed.

Principal component projection

In a similar fashion to the COVID-19 HGI, we asked each study to project their cohort onto a multiethnic genetic principal component space (Supplementary Fig. 5), by providing studies with precomputed PC loadings and reference allele frequencies from unrelated samples from the 1000 Genomes Project^{20,21} and the Human Genome Diversity Project. The loadings and frequencies were generated for a set of 117,221 autosomal, common (minor allele frequency (MAF) $\geq 0.1\%$) and LD-pruned ($r^2 < 0.8$; 500-kb window) SNPs that would be available in the imputed data of most studies. Access to the projecting and plotting scripts was made available to the studies at https://github.com/long-covid-hg/pca_projection.

eQTL, PheWAS and colocalization

For the single (Bonferroni-corrected) genome-wide significant lead variant, **rs9367106**, we used the GTEx portal (<https://gtexportal.org/>)^{22,23} to understand whether this variant had any tissue-specific effects on gene expression. As **rs9367106** was not available in the GTEx database, we first identified a proxy variant, **rs12660421** ($r^2 = 0.90$) using all individuals from the 1000 Genomes Project^{20,21} and then performed a lookup in the portal's GTEx v8 dataset²³.

To identify other phenotypes associated with **rs9367106**, we used the Biobank Japan PheWeb portal (<https://pheweb.jp/>)⁹ to perform a phenome-wide association analysis, as the MAF of **rs9367106** is highest in East Asia. Furthermore, we explored variant and locus-level associations in Estonian Biobank, FinnGen and Open Targets.

To assess whether the *FOXP4* association is shared between long COVID, and tissue-specific eQTLs, lung cancer and COVID-19 hospitalization, we extracted a 1-Mb region centered on **rs9367107** (chr6: 41,015,652–42,015,652) from the lung cancer and COVID-19 hospitalization summary statistics and the GTEx v8 data and performed colocalization analyses using the R package coloc (v5.1.0.1)^{61,62} in R v4.2.2. Colocalization locus zoom plots were created using the LocusCompareR R package v1.0.0 (ref. 63), with LD r^2 estimated using 1000 Genomes European-ancestry individuals^{20,21}.

Genetic correlation and MR

We assessed the genetic overlap and causal associations between long COVID outcomes and the same set of risk factors, biomarkers and disease liabilities as in the COVID-19 HGI flagship paper¹⁶. Additionally, we tested the overlap and causal impact of COVID-19 susceptibility and hospitalization risk. Genetic correlations were assessed using Linkage Disequilibrium Score Regression v1.0.1 (ref. 64). Where there were sufficient genome-wide significant variants, the causal impact was tested in a two-sample MR framework using the TwoSampleMR (v0.5.6) R package⁶⁵ with R v4.0.3. To avoid sample overlap between exposure GWASs (here COVID-19 hospitalization and SARS-CoV-2 reported infection) and outcome GWASs (here long COVID phenotypes), we performed meta-analyses of COVID-19 hospitalization and SARS-CoV-2 reported infection using data freeze 7 of the COVID-19 HGI by excluding studies that participated in the long COVID (data freeze 4) effort. Independent significant exposure variants with $P \leq 5 \times 10^{-8}$ were identified by LD-clumping the full set of summary statistics using an LD r^2 threshold of 0.001 (based on the 1000 Genomes European-ancestry reference samples^{20,21}) and a 10-Mb clumping window. For each exposure–outcome pair, these variants were then harmonized to remove variants with mismatched alleles and ambiguous palindromic variants (MAF > 45%). Fixed-effects IVW meta-analysis was used as the primary MR method, with MR-Egger, weighted median estimator, weighted mode-based estimator and MR-PRESSO used in sensitivity analyses. Heterogeneity was assessed using the MR-PRESSO global test and pleiotropy using the MR-Egger intercept. The genetic correlation and MR analyses were implemented as a Snakemake Workflow made available at <https://github.com/marcoralab/MRcovid>. Leave-one-variant-out-MR and European-only long COVID analyses were run as sensitivity analyses to test the robustness of MR results with COVID hospitalization as exposure and long COVID as outcome.

Summaries of the exposure GWAS are provided in Supplementary Table 26, and the association statistics for all exposure variants are provided in Supplementary Data.

Bayesian clustering of effects based on linear relationships

We compared effect size estimates between long COVID and COVID severity, and similarly, between long COVID and SARS-CoV-2 infection. COVID-19 hospitalization was used as a proxy for severity. For this purpose, we selected those variants that had earlier association evidence at the genome-wide significant level for COVID-19 severity or SARS-CoV-2 infection and examined whether these variants had joint or higher effect than expected for long COVID. The linemodells R package was utilized for comparing linear relationships (<https://github.com/mjpirinen/linemodells>)⁶⁶. This line model method performs probabilistic clustering of variables based on their observed effect sizes on two outcomes (Supplementary Note).

Statistics and reproducibility

To maximize the statistical power for detecting genetic variants associated with long COVID, we used data from as many cohorts as possible with information on long COVID and study participants without long COVID. Moreover, to ensure reproducibility, we examined the robustness and replication of the signal across nine independent cohorts that joined the Long COVID HGI after data freeze 4 where the association was initially discovered.

For additional methodological details, see Supplementary Note.

Reporting summary

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

Data availability

We have made the results of these GWAS meta-analyses publicly available for variants passing post-meta-analysis filtering for MAF $\geq 1\%$

and effective sample size $>1/3$ of the maximum effective sample size for each meta-analysis. The results from the four meta-analyses have been deposited to GWAS Catalog⁶⁷ and LocusZoom⁶⁸, where the associations can be visually explored and the summary statistics exported for further scientific discovery.

Strict case definition (long COVID after test-verified SARS-CoV-2 infection) versus broad control definition (population control):

<https://www.ebi.ac.uk/gwas/studies/GCST90454540>

<https://my.locuszoom.org/gwas/192226/>

Broad case definition (long COVID after any SARS-CoV-2 infection) versus broad control definition:

<https://www.ebi.ac.uk/gwas/studies/GCST90454541>

<https://my.locuszoom.org/gwas/826733/>

Strict case definition versus strict control definition (individuals that had SARS-CoV-2 but did not develop long COVID):

<https://www.ebi.ac.uk/gwas/studies/GCST90454542>

<https://my.locuszoom.org/gwas/793752/>

Broad case definition versus strict control definition:

<https://www.ebi.ac.uk/gwas/studies/GCST90454543>

<https://my.locuszoom.org/gwas/91854/>

Code availability

Instructions and example code for phenotyping, sample collection, genotyping, genotype and sample quality control, imputation and association analyses are shared in our central analysis plan (https://github.com/long-covid-hg/LongCovidTools/blob/main/COVID-19HostGenetics_AnalysisPlan_LongCOVID_v1.docx, https://github.com/long-covid-hg/LongCovidTools/blob/main/PhenotypeDefinitions_LongCOVID_v1.docx). Furthermore, we have used GitHub public repositories for providing code for GWAS summary statistics lift-over and meta-analyses (https://github.com/long-covid-hg/META_ANALYSIS, modified from the previously published COVID-19 HGI pipeline^{15,16}), for PCA projecting and plotting (https://github.com/long-covid-hg/pca_projection) and for MR and genetic correlation (<https://github.com/marcoralab/MRCovid>). Code used for fine mapping (<https://github.com/mkanai/slalom>)²⁷ and Bayesian clustering of effects based on linear relationships (<https://github.com/mjpirinen/linemodels>)⁶⁶ is also publicly available and has been previously published.

References

57. Mbatchou, J. et al. Computationally efficient whole-genome regression for quantitative and binary traits. *Nat. Genet.* **53**, 1097–1103 (2021).
58. Zhou, W. et al. Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies. *Nat. Genet.* **50**, 1335–1341 (2018).
59. Chang, C. C. et al. Second-generation PLINK: rising to the challenge of larger and richer datasets. *Gigascience* **4**, 7 (2015).
60. Neupane, B., Loeb, M., Anand, S. S. & Beyene, J. Meta-analysis of genetic association studies under heterogeneity. *Eur. J. Hum. Genet.* **20**, 1174–1181 (2012).
61. Wang, G., Sarkar, A., Carbonetto, P. & Stephens, M. A simple new approach to variable selection in regression, with application to genetic fine mapping. *J. R. Stat. Soc. Series B Stat. Methodol.* **82**, 1273–1300 (2020).
62. Wallace, C. A more accurate method for colocalisation analysis allowing for multiple causal variants. *PLoS Genet.* **17**, e1009440 (2021).
63. Liu, B., Gloudemans, M. J., Rao, A. S., Ingelsson, E. & Montgomery, S. B. Abundant associations with gene expression complicate GWAS follow-up. *Nat. Genet.* **51**, 768–769 (2019).
64. Bulik-Sullivan, B. K. et al. LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. *Nat. Genet.* **47**, 291–295 (2015).

65. Hemani, G., Tilling, K. & Davey Smith, G. Orienting the causal relationship between imprecisely measured traits using GWAS summary data. *PLoS Genet.* **13**, e1007081 (2017).
66. Pirinen, M. linemodls: clustering effects based on linear relationships. *Bioinformatics* **39**, btad115 (2023).
67. Sollis, E. et al. The NHGRI-EBI GWAS Catalog: knowledgebase and deposition resource. *Nucleic Acids Res.* **51**, D977–D985 (2023).
68. Boughton, A. P. et al. LocusZoom.js: interactive and embeddable visualization of genetic association study results. *Bioinformatics* **37**, 3017–3018 (2021).

Acknowledgements

We are extremely grateful to all the participants, healthcare professionals, interviewers, computer and laboratory technicians, clerical workers, research scientists, volunteers, managers and everyone participating in making possible the collection and analysis of datasets contributing to this study. We acknowledge the funding and research infrastructure support in Supplementary Note (see also the full Long COVID HGI author information in Supplementary Table 2).

Author contributions

V.L., T.N., S.E.J., H.Z. and H.M.O. contributed to scientific leadership, project management, experimental design and conception, ethics and governance, and bioinformatics. V.L., T.N., S.E.J., H.Z., H.M.O. and the Long COVID HGI were members of the steering committee. V.L., S.E.J., T.N., H.Z., A.A.R., A.H.-C., A.M., A.N., A.R.D., A.S., A.S.F.K., B.C., B.G.-G., C.B., C.B.S., C.A.R.W., D.C.P., D.M.J., E.A., E.F., E.T.C., E.V., F.M., H.E.O., J.M.L., K.A.-V., K.B., L.C.-S., L.G., L.M., M.M., M.V., O.C.L., R.E., R.E.M., R.K.C., R.R., S.A., S.S.V., T.W.W., M.B., M.M.-H. and N.S.-A. performed primary cohort data analyses. V.L., T.N., S.E.J., M.B. and J.K. performed GWAS meta-analyses. S.E.J., T.N., V.L., H.Z., S.J.A., M. Kanai, A.O.-G., B.E.F.-H., H.H.H., M.P., A.K.M. and N.S.-A. performed follow-up analyses. A. Renieri, A. Rakitko, M. Kumari, A.C., A.N., C.E., C.J., E.C.S., E.L.D., F.G., G.D.S., H.M.O., I.M.H., J.B.R., J.J.G., J.L.-E., K.C., K.K.T., K.U.L., L.A., L.H.F., L.V.C.V., L.V.W., M.I., M.M.-H., N.D.B., N.J.T., O.B.V.P., P.J.S., P.M., R.A.V., R.d.C., R.K.M., R.W., S.A.L., S.L., S.S.V., T.T.-L., Y.O., A.O.-G., M.B., A.S. and H.Z. contributed to data/sample collection. Data for initial discovery GWASs (Long COVID HGI data freeze 4) was collected by DBDS, EstBB, FinnGen, GEN-COVID, GENCOV, MexGen-COVID (Supplementary Tables 1, 3–8 and 12), ALSPAC, BoSCO, BQC19, EXCEED, GCAT (COVICAT), Genotek, GOLD, Helix, Ioannina, IrCovid, JapanTaskForce, Lifelines, MoBa, MSCIC, PMBB, SweCovid, COMRI, TiKoCo, TwinsUK, UKB and Understanding Society (Supplementary Tables 11 and 12). Replication datasets were provided by PHOSP-COVID, MVP (Supplementary Tables 9, 10 and 12), LatviaGDB, C19-GenoNet, CHIRP, EstBB, FoGS and MGB (Supplementary Table 12). V.L., S.E.J., T.N., H.Z., A.G., A.K., A.N., E.L.D., E.M., H.F.A., M.J.D., M.M.-H., M.M.M., N.S.-A., P.S., U.A.Z., A. Renieri, A. Rakitko, M. Kumari, A.C., C.E., C.J., E.C.S., F.G., G.D.S., H.M.O., I.M.H., J.B.R., J.J.G., J.L.-E., K.C., K.K.T., K.U.L., L.A., L.H.F., L.V.C.V., L.V.W., M.I., N.D.B., N.J.T., O.B.V.P., P.J.S., P.M., R.A.V., R.d.C., R.K.M., R.W., S.A.L., S.L., S.S.V., T.T.-L., Y.O., A.A.R., A.H.-C., A.M., A.R.D., A.S., A.S.F.K., B.C., B.G.G., C.B., C.B.S., C.A.R.W., D.C.P., D.M.J., E.A., E.F., E.T.C., E.V., F.M., H.E.O., J.M.L., K.A.-V., K.B., L.C.-S., L.G., L.M., M.M., M.V., O.C.L., R.E., R.E.M., R.K.C., R.R., S.A. and T.W.W. wrote and reviewed the manuscript. All other authors were involved in the design, management, coordination or analysis of contributing studies. See Supplementary Tables 2–10 for more detailed information on author contributions and roles.

Funding

Open access funding provided by Max Planck Society.

Competing interests

S.B. has ownerships in Intomics A/S, Hoba Therapeutics Aps, Novo Nordisk A/S, Lundbeck A/S, ALK abello A/S, Eli Lilly and Co and is

managing board memberships in Proscion A/S and Intomics A/S. A.B., K.M.S.B., S.W., N.L.W., F.T., E.S. and E.T.C. are employees of Helix. A.D. received an honorarium from Gilead Sciences. A.L.G. and C.J. have funded research collaborations with Orion for collaborative research projects outside the submitted work. T.H. and H.E.O.B. have options in Sano Genetics. P.J.S. is a shareholder of Sano Genetics. T.H.K. has received consulting fees from Albireo, Boehringer Ingelheim, MSD and Falk Pharma. K.U.L. is cofounder and member of the scientific board of LAMPseq Diagnostics GmbH. T.N. has received speaking fee from Boehringer Ingelheim for talks unrelated to this research. M.E.K.N. is a current employee of Novartis Pharma AG. J.B.R.'s institution has received investigator-initiated grant funding from Eli Lilly, GlaxoSmithKline and Biogen for projects unrelated to this research. He is the CEO of 5 Prime Sciences (www.5primesciences.com), which provides research services for biotech, pharma and venture capital companies for projects unrelated to this research. V.F. is an employee of 5 Prime Sciences. C.D.S. reports grants and personal fees from AstraZeneca, Janssen-Cilag and ViiV Healthcare, personal fees and nonfinancial support from BBraun Melsungen, grants, personal fees and nonfinancial support from Gilead Sciences, personal fees from BioNtech, Eli Lilly, Formycon, Pfizer, Roche, Apeiron, GSK, Molecular partners, SOBI, AbbVie, MSD and Synairgen and grants from Cepheid. L.V.W. reports research funding from GlaxoSmithKline, Genentech and Orion Pharma, and consultancy for Galapagos and GlaxoSmithKline, outside of the submitted work. J.W. is a consultant for Roboscreen

GmbH, Biogen GmbH, Immungenetics AG, Noselab GmbH, Roche Diagnostics International, Roche Pharma AG, Janssen-Cilag GmbH, Eisai GmbH, Boehringer Ingelheim and Lilly Deutschland GmbH and has received honoraries from Eisai GmbH, Biogen GmbH, AGNP e. V., Veranex, Med Update GmbH, Guangzhou Gloryren Medical Technology (China), Pfizer Pharma GmbH, Fachverband Rheumatologische Fachassistenz e. V., AWO Psychiatrie Akademie gGmbH, Neuroakademie E. V., Beijing Yibai Science und Technology Ltd., Abbott Laboratories GmbH, Lilly Deutschland GmbH, Simon & Kucher and streamedup! GmbH. The other authors declare no competing interests.

Additional information

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41588-025-02100-w>.

Correspondence and requests for materials should be addressed to Hugo Zeberg or Hanna M. Ollila.

Peer review information *Nature Genetics* thanks the anonymous reviewers for their contribution to the peer review of this work.

Reprints and permissions information is available at www.nature.com/reprints.

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a Confirmed

- ☐ ☒ The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
- ☐ ☒ A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- ☐ ☒ The statistical test(s) used AND whether they are one- or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
- ☐ ☒ A description of all covariates tested
- ☐ ☒ A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- ☐ ☒ A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
- ☐ ☒ For null hypothesis testing, the test statistic (e.g. F , t , r) with confidence intervals, effect sizes, degrees of freedom and P value noted
Give P values as exact values whenever suitable.
- ☐ ☒ For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
- ☐ ☒ For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
- ☐ ☒ Estimates of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated

Our web collection on [statistics for biologists](#) contains articles on many of the points above.

Software and code

Policy information about [availability of computer code](#)

Data collection	Provided in the manuscript Methods section, Supplementary Table 12, and Supplementary Note. Instructions and example code for phenotyping, sample collection, genotyping, genotype and sample quality control, imputation, and association analyses shared in our central analysis plan.
Data analysis	Provided in the manuscript Methods section, Supplementary Table 12, Supplementary Note, and in the Code Availability statement. Instructions and example code for phenotyping, sample collection, genotyping, genotype and sample quality control, imputation, and association analyses are shared in our central analysis plan (https://github.com/long-covid-hg/LongCovidTools/blob/main/COVID19HostGenetics_AnalysisPlan_LongCOVID_v1.docx , https://github.com/long-covid-hg/LongCovidTools/blob/main/PhenotypeDefinitions_LongCOVID_v1.docx). Furthermore, we have used GitHub public repositories for providing code for GWAS summary statistics lift-over and meta-analyses (https://github.com/long-covid-hg/META_ANALYSIS , modified from the previously published COVID-19 HGI pipeline), for PCA projecting and plotting (https://github.com/long-covid-hg/pca_projection), and for Mendelian randomization and genetic correlation (https://github.com/marcoralab/MRcovid). Code used for fine-mapping (https://github.com/mkanai/slalom) and Bayesian clustering of effects based on linear relationships (https://github.com/mjpirinen/linemodels) is also publicly available and has been previously published.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio [guidelines for submitting code & software](#) for further information.

Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our [policy](#)

Data availability (as provided in the manuscript)

We have made the results of these GWAS meta-analyses publicly available for variants passing post-meta-analysis filtering for minor allele frequency $\geq 1\%$ and effective sample size $> 1/3$ of the maximum effective sample size for each meta-analysis. The results from the four meta-analyses have been deposited to GWAS Catalog and LocusZoom, where the associations can be visually explored and the summary statistics exported for further scientific discovery.

Strict case definition (Long COVID after test-verified SARS-CoV-2 infection) vs broad control definition (population control):

<https://www.ebi.ac.uk/gwas/studies/GCST90454540>

<https://my.locuszoom.org/gwas/192226/>

Broad case definition (Long COVID after any SARS-CoV-2 infection) vs broad control definition:

<https://www.ebi.ac.uk/gwas/studies/GCST90454541>

<https://my.locuszoom.org/gwas/826733/>

Strict case definition vs strict control definition (individuals that had SARS-CoV-2 but did not develop Long COVID):

<https://www.ebi.ac.uk/gwas/studies/GCST90454542><https://my.locuszoom.org/gwas/793752/>

Broad case definition vs strict control definition:

<https://www.ebi.ac.uk/gwas/studies/GCST90454543><https://my.locuszoom.org/gwas/91854/>

Research involving human participants, their data, or biological material

Policy information about studies with [human participants or human data](#). See also policy information about [sex, gender \(identity/presentation\), and sexual orientation](#) and [race, ethnicity and racism](#).

Reporting on sex and gender

All GWASs were performed adjusting for sex. Sex-stratified analyses can be performed in future data freezes as the sample sizes grow.

Reporting on race, ethnicity, or other socially relevant groupings

Genetic ancestry was assessed in each contributing study by principal component projection to ensure robustness of our genetic association analyses. Each study ran GWAS within-ancestry, and our multi-ancestry meta-analyses combined all studies regardless of ancestry. More info provided in the Methods and Supplementary Methods.

Population characteristics

Detailed information on the recruitment of study participants, phenotyping using diagnoses from electronic health records or questionnaire information on COVID symptoms and recovery, genetic ancestry, genotyping etc. is provided by each contributing study in the Supplementary Table 12.

Recruitment

Each of the 24 initially contributing studies and 9 replication studies recruited their participants independently. Some of the studies (such as FinnGen and UK Biobank) were larger biobank-type data sets, whereas others were smaller clinical cohorts. Please see more detailed information in the Supplementary Table 12.

Ethics oversight

Participants provided written informed consent to participate in each respective study, with recruitment and ethics following study-specific protocols approved by their respective Institutional Review Boards and studies performed in accordance with the Declaration of Helsinki. Details are provided in Supplementary Table 12 where we have now added the replication cohorts.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

☒ Life sciences

☐ Behavioural & social sciences

☐ Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://www.nature.com/documents/nr-reporting-summary-flat.pdf)

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size

The Long COVID Host Genetics Initiative (HGI) is a global and ongoing collaboration project to study genetic factors associated with the risk for developing long-term health problems after SARS-CoV-2 infection. The initiative is open to all studies around the world that have data to run Long COVID genome-wide association study (GWAS). We have meta-analysed all Long COVID GWAS that contributing studies ran and shared to us. A total of 24 studies contributed to the analysis, with a total sample size of 6,450 Long COVID cases with 46,208 COVID-19 positive controls and 1,093,955 population controls from 6 ancestries. The finding was replicated in an independent dataset of nine additional cohorts with 9,500 Long COVID cases and 798,835 population controls.

To maximize statistical power for detecting genetic variants associated to Long COVID, we utilized data from as many cohorts as possible with information of Long COVID and study participants without Long COVID. Moreover, to ensure reproducibility, we examined the robustness and replication of the signal across nine independent cohorts that joined the Long COVID Host Genetics Initiative after the data freeze 4 where the initial association was discovered.

Data exclusions	Genetic variants with allele frequency <0.1% or imputation INFO score <0.6 were excluded from the GWAS meta-analyses. Study-specific information on data collection and analysis is provided in the Supplementary Table 12.
Replication	The association in FOXP4 locus was replicated using an independent dataset with nine additional cohorts with 9,500 Long COVID cases and 798,835 controls.
Randomization	The phenotype definitions were designed by our global Long COVID Host Genetics Initiative working group based on clinical information on Long COVID symptoms. Each study then defined the case and control groups based on observational data (either electronic health record diagnosis data, or questionnaire information on symptoms and recovery) within their data set. Randomization does not apply to this study design.
Blinding	Our study was not a controlled trial but a genome-wide association study (GWAS) using genotypic information combined to questionnaire and electronic health record data to define case and control groups, and thus blinding and randomization do not apply.

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems

n/a	Involved in the study
☒	☐ Antibodies
☒	☐ Eukaryotic cell lines
☒	☐ Palaeontology and archaeology
☒	☐ Animals and other organisms
☒	☐ Clinical data
☒	☐ Dual use research of concern
☒	☐ Plants

Methods

n/a	Involved in the study
☒	☐ ChIP-seq
☒	☐ Flow cytometry
☒	☐ MRI-based neuroimaging